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Vitronectin is a multifunctional glycoprotein involved in regulation of such 
processes as hemostasis, cell migration, immunity, and tumor metastasis. Many of its 
functions require interaction with various binding partners. One such partner, 
plasminogen activator inhibitor-type 1 (PAI-1), belongs to the serine protease inhibitor 
(serpin) superfamily of proteins. PAI-1 helps regulate hemostasis by affecting blood clot 
breakdown, and helps regulate cell migration and tissue remodeling by affecting 
extracellular matrix digestion. Our laboratory is pursuing structural information on 
vitronectin and the complex formed between vitronectin and PAI-1. To this end, the work 
presented in this thesis focuses on two aims: characterizing the interaction of vitronectin 
and PAI-1 with metal ions, and developing reagents to be used in structural studies of 
vitronectin. We have used electron paramagnetic resonance (EPR) spectroscopy to study 
metal binding by vitronectin and PAI-1.  We have tested vitronectin and PAI-1 for 
binding of Mn2+ and Cu2+, and also established the feasibility of studying protein-Cu2+ 
interaction in solution by EPR, using bovine serum albumin (BSA) and Cu2+. In another 
set of experiments, we have used activity assays to assess the effect of metal ions on 
PAI-1 activity and on stabilization of PAI-1 by vitronectin. Regarding reagents, we have 
expressed and purified active, perdeuterated PAI-1, which can be used in complex with 
vitronectin in neutron scattering and NMR experiments. We characterized several 
monoclonal antibodies to vitronectin, and identified one suitable for use in co-
crystallization screens. These accomplishments will aid in development of a more 
detailed picture of the interaction between vitronectin and PAI-1. 
 iv
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INTRODUCTION TO VITRONECTIN AND PLASMINOGEN 





Overview of Vitronectin 
Vitronectin is a multi-domain, adhesive glycoprotein found in both the extracellular 
matrix (ECM) [1] and plasma, where it circulates at a relatively high concentration 
(micromolar range) [2,3]. It is involved in regulation of such physiological processes as 
coagulation, wound healing, tissue remodeling, angiogenesis, and the complement-
mediated cellular immune response. To facilitate participation in these varied processes, 
vitronectin is able to bind to many and varied ligands, including heparin, plasminogen 
activator inhibitor-type I (PAI-1), complement components, cell surface receptors and 
integrins [4,5]. The 459 amino acids of vitronectin include side chains which are 
glycosylated, sulfated, or phosphorylated.  The glycosylations, along with the 62-kDa 
molecular weight of this protein and its tendency to self-multimerize, make three-
dimensional structural studies of the protein particularly challenging. High-resolution 
structural information for vitronectin is limited to the somatomedin B (SMB) domain (the 
N-terminal 44 residues of vitronectin): solution structures were established by NMR on 
both the human plasma-purified domain (2.29 Å resolution for core region) [6] and a 
recombinant SMB domain [7]; a crystal structure was solved for another recombinant 
SMB domain in complex with a key vitronectin-binding protein, (PAI-1) (2.3 Å 
resolution) [8]. In addition, a low-resolution model of vitronectin from small-angle x-ray 
scattering (SAXS) [9] and computational models using a threading algorithm for three 
main domains of vitronectin (see Figure 1) [10] have been published by this laboratory. 
The SAXS model indicates the shape of vitronectin to be oblong and bi-lobed, somewhat 
like that of a peanut (see Figure 2). 
The primary sequence of vitronectin can be divided into three main domains plus a 
connecting region: the aforementioned N-terminal SMB domain, the connecting region, a 
central hemopexin homology domain, and a C-terminal heparin-binding domain [11]. As 
a regulatory protein, vitronectin executes its many functions by binding to its various 
ligands. Many of these binding interactions have been localized to one of the main 
domains. Figure 3 shows the linear domain arrangement of vitronectin together with key 
ligand binding locations. Details of each domain are given in the following section. 
Domain Structure of Vitronectin 
The 44-residue SMB domain shares primary sequence with somatomedin B, a peptide 
of unknown function present in the circulation [11]. Within this compact, 5-kDa domain 
is a network of four disulfide bonds, whose pairings remain controversial. Through 
limited proteolysis, CNBr cleavage, acid cleavage, and peptide mapping, our laboratory 
proposed one arrangement [12], but two other groups have proposed different 
arrangements [8,13]. While the proposal from our lab came from analysis of SMB 
domain cleaved and isolated from human plasma vitronectin, the others came from 
working with recombinant forms of SMB produced in E. coli.  The latter means of 
obtaining the peptide leads to questions of whether correct folding and disulfide pairing 





igure 1: Domain structure predictions for vitronectin obtained from sequence-
ructure alignment and fold recognition (threading). 
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Figure 2: SAXS Model of Vitronectin. 
The purple dots represent the consensus envelope for the protein obtained from SAXS 
data, onto which a model assembled from domain structures together with SAXS data 
was overlaid [9]. The blue ribbon structure near the top is the NMR structure of the SMB 
domain [6]. The green and red structures are the central and C-terminal domains, 
respectively, predicted from threading [10]. The orange structure near the center 














Figure 3: Vitronectin domains and locations of key ligand binding sites. 
The linear sequence of vitronectin can be divided into three main domains plus a 
connecting region. The protein executes its regulatory functions by binding to a wide 
array of ligands. The domain locations of key ligand binding sites are indicated above 
each domain in the figure. 
 
 5
The primary binding site for PAI-1 is in the SMB domain, as is that for the urokinase-
type plasminogen activator receptor (uPAR). From the NMR structure of the SMB 
domain (Figure 4), it can be seen to represent a unique fold, having little secondary 
structure, with the exception of the single-turn α-helix [6]. Residues 24 – 30, which 
include this helix, have been identified through mutagenesis work and the use of 
monoclonal antibodies as the site of PAI-1 binding [14]. 
Immediately following the SMB domain is the integrin binding sequence, arginine-
glycine-aspartate (RGD).  This sequence mediates cell adhesion by vitronectin [15-17]. 
The connecting region, spanning from residue 45 at the start of the RGD sequence, to 
residue 130, tethers the SMB domain to the central hemopexin-homology domain. This 
region is predicted to be unstructured [10]. It also houses binding sites for collagen, for 
interaction with the ECM, and the thrombin-antithrombin complex. 
The central hemopexin homology domain is the largest, covering residues 131-342, 
and sharing significant sequence homology with hemopexin [18]. Hemopexin domains in 
proteins have been shown to produce the β-propeller fold [19], which is implicated in 
protein-protein interactions, as in the metalloprotein, collagenase [20]. Not surprisingly, 
structure predictions by threading predict with high confidence that the four hemopexin 
repeats of this domain are folded into a four-bladed β-propeller [10]. 
The C-terminal heparin-binding domain extends from residue 343 to 459. The N-
terminal end of this domain begins with three additional hemopexin repeats, which are 
predicted to form only two blades of a β-propeller [10]. Following these repeats, a cluster 
of positively charged amino acids comprise the heparin binding site, which supports 





















Figure 4: NMR Solution structure of the SMB domain of vitronectin. 
The only secondary structural element of the compact SMB domain is a single-turn α-
helix (shown in green), which is the site of PAI-1 binding. The four disulfide bonds are 
shown in yellow. The peptide used for this structure includes the RGD sequence just past 
the C-terminus of the SMB domain; this sequence mediates cell binding of vitronectin 
through integrins. Adapted from [6]. 
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regulates hemostasis by affecting the thrombin-antithrombin interaction. Vitronectin 
competes with thrombin and antithrombin for heparin binding [21]. Without heparin, 
antithrombin is less effective at inhibiting thrombin, which is free to initiate blood 
clotting. 
Another collagen binding site is in this domain, as well as the site of complement 
component interaction. Secondary PAI-1 and uPAR binding sites may exist in the C-
terminal domain, but their existence has been controversial. Recently, work from our 
laboratory using an SMB-deletion mutant of vitronectin has shown the persistence of 
PAI-1 binding in the absence of the SMB binding site [22]. This is strong evidence in 
support of the second PAI-1 binding site. However, this work also shows abolition of 
uPAR binding upon deletion of the N-terminal uPAR binding site, indicating that no 
secondary uPAR binding site exists outside the SMB domain of vitronectin.  
Overview of PAI-1 
PAI-1 is a member of the serine protease inhibitor (serpin) superfamily of proteins. 
As one of many binding partners of vitronectin, PAI-1 is found in the circulation and in 
the ECM. It functions as a regulator of clot formation and fibrinolysis, by inhibiting 
cleavage of plasminogen to active plasmin, which proteolyzes fibrin. 
The protein now known as PAI-1 was first described in 1984, as an unknown 
inhibitor of plasminogen activators present in human serum [23]. This type of inhibition 
was new to researchers, as it indicated a point of regulation of fibrinolysis earlier than 
occurs for the active proteases, such as the well-known antiplasmin. It was suggested this 
protein  represented a new class of inhibitors, termed the “antiactivators.”  
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Within a few years, an unknown binding protein of PAI-1 was detected in plasma, 
present in high molecular weight complexes [24,25]. This protein was isolated and 
identified as S-protein, or vitronectin [26], and was shown to increase the half-life of the 
labile PAI-1 at 37°C by 2-3-fold, compared to purified PAI-1. It was proposed that 
vitronectin may stabilize PAI-1 in the blood as well. Indeed, it is now known that 
circulating PAI-1 is almost exclusively bound to vitronectin [26].  
As a serpin, PAI-1 shares structural similarity to other family members, such as 
antithrombin, but it is unique in its short half-life of approximately 90 min. Through a 
spontaneous conformational change, active PAI-1 is converted to an inactive, latent form 
[27]. It is probable that this structural lability contributes to the regulatory function of the 
protein. Key structural features of PAI-1 are a central β-sheet (β-sheet A), nine α-helices 
(hA-hI), and a reactive center loop (RCL) extending away from the protein (see Figure 
5). 
The serpin mechanism of inhibition involves the flexible RCL, containing the 
recognition sequence of the target serine protease, which can bind to the RCL and begin 
the process of substrate cleavage via the catalytic triad. However, once the peptide bond 
is cut, while the enzyme is covalently bound to the serpin as an acyl-enzyme 
intermediate, the cleaved RCL translocates and inserts as a sixth strand in the central 
β-sheet, taking the trapped protease with it. This disrupts the active site of the enzyme 
such that it cannot complete the cleavage mechanism to release itself from the inhibitor. 
The same mode of RCL insertion into β-sheet A is the mechanism by which active PAI-1 











Figure 5: Active and latent forms of PAI-1. 
In active PAI-1, the RCL is extended as a target for a serine protease. PAI-1 readily 
converts to an inactive, latent form, by insertion of the RCL into the β-sheet. Adapted 
from [27].  
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The x-ray crystal structure of the SMB domain of vitronectin in complex with PAI-1 
helped elucidate how vitronectin stabilizes PAI-1 in its active conformation [8]. The 
primary vitronectin binding site is located at the base of β-sheet A, near the opposite end 
of the protein from the extended RCL. Here, through interaction with both hE and hF, 
vitronectin obstructs β-sheet A from opening to allow RCL insertion. Thus, the RCL 
remains solvent-exposed and available as a target for proteases. 
Recently, attention has been given to mapping a secondary vitronectin binding site on 
PAI-1. Since the primary site involves interaction with the SMB domain, our laboratory 
engineered a recombinant SMB-deletion mutant vitronectin for studies of the secondary 
PAI-1 binding site on vitronectin as well as a complementary site on PAI-1 [22,29]. 
Using a variety of PAI-1 mutants, and surface plasmon resonance (SPR) experiments, a 
region of residues involved in binding to vitronectin outside the SMB domain was 
identified. This region is near, but separate from, the region that binds to the SMB 
domain. 
The functions of both vitronectin and PAI-1 are affected by their mutual interaction. 
Vitronectin stabilizes PAI-1 in its active conformation, and PAI-1 causes vitronectin to 
multimerize. Multimeric vitronectin is deposited in the ECM, where vitronectin mediates 
its cell adhesion effects. In this way, PAI-1 helps localize vitronectin from the plasma to 
areas of injury or inflammation to regulate hemostasis. 
What lines of research led to our current understanding of vitronectin? How did this 
understanding develop? What were the key early discoveries and areas of contention?  
 11
 
Development of Thought on Vitronectin: A Story of Convergent 
Experimental Paths 
 
Beginnings of the cell adhesion path of study 
A driving force in cell biology research in the mid-20th century was the quest to 
identify components necessary to support mammalian cell growth in serum-free medium. 
By 1955, Eagle had catalogued amino-acid and vitamin requirements for many cell 
types[30], but most cultures still had to be supplemented with at least 5% serum. This 
was acceptable for some experiments, but in other cases, the complex and indeterminate 
components of serum led to difficulty interpreting experimental results [31]. More than a 
decade later, Holmes described his “α-1 protein” from human serum, having studied its 
positive effect on cell growth and morphology, after partial purification on glass beads 
[32]. Years would pass before this protein would be isolated and called vitronectin. 
However, in light of current knowledge that vitronectin is rather difficult to isolate and 
work with, it is understandable that optimism over the potential benefits of such a protein 
growth factor was not soon followed by reports of successful exploitation in cell culture. 
So sought-after was the identification of growth factors in serum, that a peptide found 
in the circulation was prematurely given the name “somatomedin B” (SMB) to highlight 
its proposed role as a somatotropin-dependent mediator of cell growth [33]. In 1978 
Fryklund and Sievertsson published the primary structure of the SMB peptide [34], 
information that eventually would prove useful in the study of vitronectin. A few years 
later, however, the same group that initially identified SMB established that the 
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mitogenic activity attributed to it was actually due to contaminating epidermal growth 
factor [35]. Yet, the name of the peptide remains today, as does the mystery of its 
purpose. 
Beginnings of the complement system path of study 
The protein now known as vitronectin next appears in the literature on its other path 
of early study. Kolb and Muller-Eberhard, investigating complement components in 
serum, detected an unknown protein in the C5b-9 complex, also known as the membrane 
attack complex (MAC) of complement [36]. Several reports combined to elucidate the 
function of this protein in binding to the precursor C5b-7 complex, to maintain complex 
solubility as complement components C8 and C9 are added; the resultant soluble MAC is 
unable to insert into cell membranes for lysis (as the normally amphiphilic MAC does) 
[37-40]. Thus, this protein protects cells from complement-induced destruction; the name 
“S-protein” is meant to reflect its competition with membrane sites for binding to the 
MAC [37]. Now interest in this “newly identified” protein was sufficient to warrant 
development of effective purification procedures, some of which are still the basis of 
protocols used today to isolate native, monomeric vitronectin [41,42]. Development of 
these procedures was neither quick nor trivial, as S-protein was noted to have a “tendency 
to aggregate and adsorb to various surfaces,” resulting in quite low yields from early 
isolation attempts [43].  
Because S-protein was found in the serum and active in the complement system, 
researchers looked for its involvement also in the coagulation system, as a potential 
regulator of hemostasis. S-protein was found in ternary complex with the serine protease, 
thrombin, and its inhibitor, antithrombin-III [44].  
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Advances in the cell adhesion path of study 
While several groups were busy characterizing S-protein from the perspective of 
involvement in the complement and coagulation systems, Barnes and coworkers, on the 
cell adhesion path of investigation, coined the term “serum spreading factor” (SSF) to 
describe partially isolated serum protein [31,45]. They showed that, for a human 
mammary tumor cell line, SSF supports not only the same cell growth rate as does serum, 
but also the same spreading morphology – a morphology similar to that reported by 
Holmes [32,45]. The activity of the protein, together with the observation of similar 
electrophoretic patterns, led to the conclusion that their SSF and Holmes’ α-1 protein are 
the same. Contemporary studies by Knox and Griffiths [46] and Knox and Whateley [47] 
provided similar evidence of the adhesive, spreading, and growth effects of this protein 
on cultured cells.  
Skeptics were suspicious that this newly discovered protein was merely fibronectin or 
a fragment thereof. While both proteins do contribute to cell adhesion, spreading and 
growth, investigators offered much evidence that SSF was a unique protein, unrelated to 
fibronectin [45,46,48]. For example, fibronectin antibodies blocked cell adhesion to 
fibronectin but not SSF [49]; conversely, SSF antibodies blocked spreading activity of 
SSF but not of fibronectin [50]; and no fibronectin homology was found from 
examination of N-terminal residues of multiple CNBr fragments of SSF [11]. 
The same reasoning that lead to skepticism about the uniqueness of SSF, also 
provided inspiration for new SSF studies. Tissues that were known to harbor fibronectin 
were probed for SSF. Soon the protein was found to exist not only in the circulation, but 
also in the ECM of many tissues and on cell surfaces, distributed similarly to fibronectin, 
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but having intensities clearly distinct from those of fibronectin [1]. Once the adhesive 
properties of SSF in the ECM had been described, expanding the realm of the protein past 
the serum, the less-restrictive moniker “vitronectin” was proposed, harkening back to 
Holmes’ single-step isolation on glass beads [1]. 
Similarly to fibronectin, vitronectin was shown to be arranged in functional domains 
along the length of its primary structure [11]. Sequencing of the first 30 N-terminal 
residues led to the surprising discovery that this part of the protein was identical to the 
somatomedin B peptide identified several years earlier [33,34]. Also in this study, peptide 
mapping using CNBr fragments provided evidence that the cell-binding site is near the 
N-terminus but outside the SMB domain; soon the same group determined that the cell-
binding site is the RGD sequence, the same as that of fibronectin [15].  A heparin binding 
region was mapped to a 12-kDa fragment near the C-terminus of the protein. This 
fragment was the only one found to bind to heparin-sepharose [11]. From alignments of 
the sequenced N-termini of the CNBr fragments used in the study, this heparin-binding 
region was shown to be rich in basic amino acids, well suited to interaction with the 
negatively charged heparin molecule. 
Further advances were made as several groups developed monoclonal antibodies to 
vitronectin, for use in both immunoaffinity purification and probing samples for anti-
vitronectin reactivity, as in the tissue study mentioned above [1,50]. In another example, 
platelet extracts were shown to have anti-SSF binding activity, while erythrocytes do not 
[50]. 
Two early purification schemes which were independently developed for SSF showed 
apparently contradicting heparin-binding properties of the protein at physiological ionic 
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strength and pH. Heparin-affinity chromatography was a logical purification step, due to 
the presence in plasma of heparin and multiple heparin-binding molecules; fractionation 
by heparin interaction would result in SSF enrichment of either the bound or the unbound 
portion of the sample. In the method of Barnes and Silnutzer, SSF was bound to heparin-
sepharose by loading in 0.1 M NaCl at pH 6.0; the protein was eluted by raising the pH to 
7.2, near physiological [2]. In the method of Ruoslahti’s laboratory, SSF was bound to 
heparin-sepharose by loading in  PBS, and eluted at the high salt concentration of 0.5 M 
NaCl [1]. After this report, the former group noted that the heparin-affinity step in 
Ruoslahti’s method followed elution from an immunoaffinity column with “potentially 
denaturing” 8M urea [51]. Speculating that this difference in isolation procedures led to 
the apparent contradiction in whether SSF can bind heparin under physiological 
conditions, they performed a set of experiments to test this idea. They found that 
exposure of SSF to denaturing treatments of either urea, heat, or acid, does result in 
heparin-binding activity at physiological ionic strength and pH; but for native SSF under 
physiological conditions – even in unfractionated plasma – only 25% of the protein 
exhibits heparin-binding activity [51]. This result was confirmed later in a study by 
Hogasen et al. [52] related to complex formation in the complement  system. 
In 1985, Hayashi et al. – using a denaturing step in their purification of vitronectin – 
proposed the “cryptic-to-open” model to explain the heparin-binding disparities 
documented for vitronectin [53]. This model contends that the heparin site in native 
vitronectin is concealed, and is exposed only upon a conformational change, such as 
results from denaturation. Curiously, this conclusion was reached after assessing heparin 
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affinity only by column chromatography, without any supporting experiments in solution 
or by alternative means of heparin immobilization. 
As a means of explanation for the differences observed in heparin-binding activity of 
vitronectin, this model (also known as the “cryptic-site” model) was generally accepted 
for many years, and even invoked to explain similar experimental results concerning 
collagen binding by vitronectin [54]. However, with the first binary solution testing of the 
vitronectin-heparin interaction, using a labeled heparin probe, work from our laboratory 
strongly supported an alternative explanation for the apparent increase in heparin affinity, 
involving the alteration of vitronectin to a multimeric form upon denaturation. The 
perceived increase in affinity is an effect of one heparin molecule being able to interact 
with more than one binding site on adjacent molecules of denatured – and multimeric – 
vitronectin [55]. 
Convergence of the two paths 
 In a seminal paper in 1985 by Jenne and Stanley, who had been working to clone S-
protein from cDNA for studies of its involvement in the complement system, the authors 
deduce that S-protein and vitronectin are the same protein [56]. In reaching this 
conclusion, which was not even a speculation at the outset of their work, they assimilated 
many clues. The primary clue came from a database search using the newly deduced 
amino acid sequence of S-protein. The N-terminal sequence matched that of the SMB 
peptide, which had also recently been identified as the N-terminal of SSF [11], also 
known as vitronectin by then. Further searching of the SSF literature provided additional 
evidence: partial peptide sequences from SSF coincided with residues in their sequence 
[11]; the amino acid compositions by percentages were very similar [2]; and multiple-
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banded electrophoretic patterns from SDS-PAGE, from several laboratories, were similar 
[1,11,41,43]. 
Importantly, the identity of these two proteins revealed connections among the 
complement defense system, the coagulation cascade, and cell-substrate adhesion. The 
body of knowledge of each “separate” protein was instantly expanded to incorporate that 
of the “other” protein. Monoclonal antibodies could be shared; isolation procedures could 
be compared, combined, and optimized; assays could find new applications. 
Coincidentally, while the Jenne and Stanley paper was in press, the cDNA sequence 
for SSF/Vn was published [15], but with no recognition of the identity with S-protein. 
However, these authors did not have access to even partial sequence information for S-
protein. 
Also at this time, another group was actively seeking evidence in the literature of an 
alternate description of the SSF/Vn protein, reasoning that its high plasma concentration 
may have led to its earlier discovery and characterization, yet by a different name [57]. 
This line of thought led them to study S-protein. They not only cite literature evidence, 
but also support the idea by several of their own experiments, including S-protein mAb 
inhibition of fibroblast spreading and SSF/Vn mAb reactivity with complement-activated 
serum. The two papers reporting the cDNA sequences appeared during the preparation of 
their work for submission and while in press. However, theirs was the first experimental 
evidence that SSF/Vn and S-protein are the same protein, and this evidence solidified the 
argument.
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The early shared path: A rocky road 
 Once researchers from different areas of study learned that they were studying the 
same protein, opposing views on the function of the protein quickly followed. The 
lability and self-aggregating tendency of vitronectin make interpretation of experimental 
results challenging and often ambiguous. In fact, not everyone embraced the greatly 
widened body of knowledge on “their” protein provided by research on the “other” 
protein. 
As an example, one researcher of complement and S-protein even suggested that the 
cell adhesion and spreading activities reported for SSF were artifacts of the assay system 
used [18]. The same study showed the primary structural homology of vitronectin with 
hemopexin, and it was proposed that vitronectin might, therefore, have a scavenging 
function for terminal components of the complement and coagulation systems. Calling 
heparin the “priniciple ligand” of vitronectin, and placing the protein in the pexin family 
due to the large proportion of its sequence taken up by hemopexin repeats, this paper 
proposed yet a fourth name for the protein: heparopexin. However, the  scavenging 
function, while a logical proposal, was not to be supported experimentally. Vitronectin is 
now classified among other proteins, including metalloproteins such as collagenases and 
gelatinases, which bear hemopexin domains but are functionally unrelated to hemopexin 
[20]. Instead, as described above, the hemopexin domain has been shown to produce the 
β-propeller fold [19], which is implicated in protein-protein interactions [20]. Our 
laboratory is currently investigating whether this domain in vitronectin is involved in the 
self-mulitmerization of the protein. 
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Questions regarding the functions and interactions of vitronectin and PAI-1 
Because vitronectin and PAI-1 are both involved in such a wide range of processes, 
the field of study of these two proteins is quite broad. Questions of interest for this work 
are centered on the functional and structural effects that vitronectin and PAI-1 exert upon 
each other through their interaction. What conformational changes occur in vitronectin 
when PAI-1 binds to it? How do these changes lead to multimerization of vitronectin? Do 
metal ions affect the interaction or function of vitronectin and PAI-1? The work 
presented here aims to probe the structural and functional aspects of vitronectin and 
PAI-1, to aid in development of a more detailed picture of the interaction between these 




The work presented in this thesis involves three projects designed to probe structural and 
functional aspects of vitronectin and PAI-1. The aims of these projects are given below, 
while the projects and their results are described in Chapters 2, 3, and 4. Specific aim 1 is 
addressed by the first project; specific aims 2a and 2b are addressed by the second and 
third projects, respectively. 
Specific Aim 1 
Characterize metal binding by vitronectin, PAI-1, and the vitronectin-PAI-1 complex. 
Aim 1a: Use EPR spectroscopy to test for metal binding by vitronectin, PAI-1, and 
the vitronectin-PAI-1 complex. 
Aim 1b: Determine the effect of metals on the activity of vitronectin and PAI-1.   
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Specific Aim 2 
Develop reagents for use in structural studies of vitronectin. 
Aim 2a: Express, purify, and confirm activity of deuterated PAI-1, to be used in 
complex with vitronectin in future neutron scattering experiments. 
Aim 2b: Characterize several monoclonal antibodies to vitronectin to identify their 
interaction with monomeric and multimeric vitronectin, and the vitronectin-
PAI-1 complex. Identify candidate antibody(ies) for crystallization screens 





CHARACTERIZATION OF VITRONECTIN AND PAI-1 




Evidence of Metal Binding 
Based on evidence that both vitronectin and PAI-1 bind metals, we hypothesized that 
both PAI-1 activity and interaction of vitronectin with PAI-1 are affected by metals. Such 
evidence of metal-binding includes the observation that metal added to vitronectin causes 
the protein to migrate differently on a polyacrylamide gel (Ze’ev Gechtman, personal 
communication). Metals affect binding of integrins by vitronectin, as shown by 
elimination of binding of the vitronectin/PAI-1 complex to integrin GPIIbIIIa, in the 
presence of EDTA [58]. Also, Mg2+and Ca2+ are required components of the integrin-
binding buffer used for vitronectin-integrin binding assays in our laboratory, as omission 
causes spurious outcomes of binding experiments (Sumit Goswami, personal 
communication). Furthermore, both vitronectin and PAI-1 are involved in altering the 
ECM, where metals are known to be important. 
Metals also influence the purification of recombinant PAI-1; our laboratory uses an 
immobilized nickel-NTA column to bind PAI-1 (without a His-tag) during purification. 
Using immobilized metal affinity chromatography (IMAC), a collaborator and supplier of 
recombinant PAI-1 has demonstrated that PAI-1 binds to immobilized Co2+, Cu2+, Mn2+, 































Figure 6: Composite elution profile for PAI-1 bound to five metal-affinity columns. 
Five affinity columns, each charged with a different metal (Co2+, Cu2+, Mn2+, Ni2+, or 
Zn2+) were loaded with a bacterial cell lysate containing PAI-1. Bound PAI-1 was eluted 
with an imidazole gradient (either 0–210 mM imidazole or 0–300 mM imidazole). The 
y-axis shows the concentration of imidazole in the gradients, while the x-axis indicates 
the volume of eluate collected. The vertical lines around a metal indicate the imidazole 
concentration range at which PAI-1 eluted from the corresponding metal-charged resin. 
Metals requiring a higher imidazole concentration for PAI-1 elution are regarded as 
binding PAI-1 more tightly than metals requiring a lower imidazole concentration for 
PAI-1 elution. (Data provided by Ingrid Verhamme and Duane Day, Molecular 
Innovations, Inc.) 
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Verhamme and Duane Day, Molecular Innovations, Inc., personal communication).  
These data give qualitative, but not quantitative, relative binding “affinities,” based on 
the concentration of imidazole required to elute the bound protein from each metal 
affinity column. Metals requiring a higher imidazole concentration for PAI-1 elution are 
regarded as binding PAI-1 more tightly than metals requiring a lower imidazole 
concentration for PAI-1 elution. 
Site-directed mutagenesis work with PAI-1 by a collaborator (Duane Day, Molecular 
Innovations, Inc., personal communication) has provided evidence of a potential metal-
binding site on PAI-1. Whereas wild-type human PAI-1 (hPAI-1) binds to the TALON 
Co2+ affinity resin, the mutant, R76E hPAI-1, loses this ability. Residue R76 is located in 
a region of positively charged amino acids, near the secondary vitronectin-binding site on 
PAI-1, as indicated in Figure 7. Supporting the notion that R76 is part of a metal-binding 
site is the observation that neither mouse PAI-1 (mPAI-1) nor rat PAI-1 (rPAI-1) binds to 
TALON resin, and neither of these has an arginine at position 76. However, rabbit PAI-1, 
which does have arginine at residue 76, does bind TALON resin. 
Mutations to mPAI-1 in the region near residue 76 have been observed to induce 
TALON binding in this species. K115R mPAI-1 exhibits partial TALON binding, while 
K115R / Q77H mPAI-1 exhibits full TALON binding. The locations of these residues are 
indicated in Figure 7. It is noteworthy that both of these mutations involve replacement of 
a positively charged amino acid with either another positively charged amino acid 
(K115R) or an uncharged (at physiological pH) amino acid (Q77H). R76E hPAI-1, which 
loses TALON binding, also involves replacement of a positively charged residue with 
















Figure 7: Putative metal-binding site on PAI-1. 
In this structure of PAI-1 (PDB accession file 1OC0), three residues determined by 
mutagenesis to be involved in metal binding are colored blue. The regions of the primary 
and secondary binding sites for Vn are indicated with ovals. Figure was rendered using 
the Molecular Biology Toolkit [59]. 
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residues is necessary to alter PAI-1 binding to the TALON Co2+ affinity resin. 
Furthermore, R76 and the mutated arginine at position 115 (which partially restores metal 
binding), as well as metal ions, are all positively charged. Therefore, direct charge-charge 
interaction of key PAI-1 residues and metal ions does not appear to mediate metal 
binding by the protein. It is possible that second-sphere complexes involving water 
molecules mediate PAI-1 metal binding instead. Based on the evidence of PAI-1 metal 
binding, together with the preceding evidence of vitronectin metal binding, we chose to 
characterize metal binding by both proteins, as well as their complex. 
Electron Paramagnetic Resonance Studies 
We used electron paramagnetic resonance (EPR) to test for metal binding by each 
protein separately, and by the complex formed between vitronectin and PAI-1. EPR is a 
spectroscopic technique that detects species that have unpaired electrons. Examples of 
metals with unpaired electrons are Mn2+, Cu2+ and Co2+, while Mg2+, Ca2+, Zn2+ and Ni2+ 
are examples of metals without unpaired electrons. Unpaired electrons can be induced to 
align – either parallel or antiparallel – to an external magnetic field, making the material 
temporarily magnetic. This property is known as paramagnetism. EPR is similar to NMR 
spectroscopy, in that an applied magnetic field is used to induce subatomic particle 
transitions that can be detected and used to characterize a sample. Whereas NMR detects 
nuclear transitions, EPR detects unpaired electron transitions. EPR can be applied to 
study metal binding by macromolecules such as proteins. The spectrum of the free metal 
alone in solution can be compared to the spectrum of the metal in solution with a protein. 
If the protein binds the metal, the signal decreases because the metal is bound to the 
much larger protein molecule. The resulting spectrum will reflect the fraction of free 
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metal remaining. Thus, changes in paramagnetic spectra provide evidence of metal 
binding by proteins. 
We chose Mn2+ and Cu2+ for our metal-binding studies. These metals are two of the 
three paramagnetic metals observed to have PAI-1 affinity in IMAC, as described above. 
The third paramagnetic metal, Co2+, was rejected from consideration because its short 
correlation time necessitates liquid nitrogen temperature to acquire an EPR spectrum, and 
we do not have access to the equipment for such experimental conditions. Conversely, 
Mn2+ has the longest correlation time among the three paramagnetic metals, allowing 
acquisition of useful EPR spectra at room temperature. Therefore, Mn2+ was an attractive 
choice for our studies. Cu2+ was chosen because it was observed to bind PAI-1 more 
tightly than Mn2+, Co2+, or Zn2+ in IMAC; only the Ni2+ affinity column required a higher 
concentration of imidazole to elute bound PAI-1. Although more Cu2+ EPR spectra in the 
literature were acquired at liquid nitrogen temperature (see e.g. [60] and [61]), rather than 
room temperature, we anticipated PAI-1 to bind Cu2+ tightly enough to permit detection 
of binding using room-temperature spectra. In addition, we planned first to confirm the 
validity of using EPR to detect Cu2+ binding to a protein, by acquiring and comparing 
Cu2+ spectra in the presence and absence of bovine serum albumin (BSA), a protein 
known to bind Cu2+.  
BSA has a high-affinity Cu2+-binding site at its N-terminus, with a Kd of 
controversial value, but estimated to be as high as 10-12 to 10-13  M [62]. A recent report 
on human serum albumin, which has the same X-Y-His metal-binding motif at its N-
terminus, used competitive UV-vis spectroscopy titrations to determine the Cu2+-binding 
affinity of this site to be 1 pM at pH 7.4  [63]. A second  Cu2+-binding site on BSA has 
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been estimated to have micromolar affinity [62]; this site is also termed the “multi-metal 
binding site” because Ni2+, Zn2+, and Cd2+ can compete for binding here [64]. Three 
additional specific, lower-affinity Cu2+-binding sites have been shown to exist in BSA 
[62]. Therefore, the study of Cu2+-binding by BSA was deemed appropriate as a test of 
the validity of the use of EPR to characterize Cu2+-binding by our proteins. 
Our experimental strategy for metal-binding studies of PAI-1 and vitronectin was 
titration of each protein, and the complex of both proteins, with a range of Mn2+ or Cu2+ 
concentrations, to determine the resulting concentrations of free Mn2+ or Cu2+. We used 
Scatchard analysis to estimate binding stoichiometry and a dissociation constant. 
Kinetic Assay for PAI-1 Activity and Stability 
To test for an effect of metals on PAI-1 activity, as well as test for an effect on 
stabilization of PAI-1 by vitronectin, we used a kinetic assay. This assay employs a 
chromogenic substrate for trypsin, a serine protease; product formation can be monitored 
by an increase in absorbance of light of a particular wavelength. PAI-1 activity can be 
assessed by its ability to inhibit trypsin, resulting in less product formed and a lower end 
absorbance. Because of the inherent tendency of PAI-1 to convert to its inactive, latent 
form, we can use this assay to monitor loss of PAI-1 activity over time; we can then 
compare this trend to that observed for PAI-1 in the presence of metals. To test for a 
difference in the stabilizing effect that vitronectin normally has on PAI-1, we can perform 
the assay with vitronectin added to PAI-1, in the presence and absence of metals. 
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Materials and Methods 
Materials 
Native vitronectin from human plasma was isolated essentially as described by 
Dahlback and Podack [41], with modifications as in Bittorf, et al. [42]. Recombinant 
PAI-1 was either purchased from Molecular Innovations, or prepared with slight 
modifications to the method described in Chapter 3 of this work, using SP sepharose, 
Ni2+-affinity, and SP-100 gel filtration chromatography for purification. BSA (Fraction 
V; heat-shock treated) and MgCl2 were from Fisher Scientific. Bovine pancreatic trypsin 
and CuSO4 were from Sigma; high-purity MnCl2 was from Johnson Matthey. Sequencing 
grade trypsin was from Promega. PD-10 disposable desalting columns were from GE 
Healthcare. 
Preparation of Protein for EPR Experiments 
All protein manipulations were carried out at 4°C. For Cu2+-binding studies with 
BSA, the protein was dissolved in 10 mM ACES buffer, pH 7.0, 0.5 mm EDTA (added to 
chelate potential trace metals in the preparation). To remove EDTA, along with any 
chelated metal ions, BSA was applied to a PD-10 desalting column equilibrated in 10 
mM ACES buffer, pH 7.0. Protein-rich fractions were identified by absorbance at 280 
nm, pooled, and concentrated in a 4-ml Amicon Ultra centrifugal filtration device 
(Millipore). Concentration was determined by absorbance at 280 nm in a Varian Cary Bio 
50 UV-Visible spectrophotometer. For Mn2+-binding studies with vitronectin, the protein 
was prepared from an (NH4)2SO4 suspension; vitronectin was pelleted by centrifugation, 
resuspended in 25 mM Tris, pH 7.4, 0.15 M NaCl, 1 mM EDTA (added to chelate 
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potential trace metals in the preparation), and dialyzed into the same buffer without 
EDTA. To remove EDTA, along with any chelated metal ions, the protein was applied to 
a PD-10 desalting column equilibrated in 25 mM Tris, pH 7.4, 0.15 M NaCl; as described 
for BSA, protein-rich fractions were pooled and concentrated. 
For Mn2+-binding studies with PAI-1, which was stored at -80°C in either 50 mM 
sodium phosphate, pH 6.25, 0.30 M NaCl, 1 mM EDTA, or 50 mM sodium phosphate, 
pH 6.6, 0.1 M NaCl, 1 mM EDTA, the protein was diluted 1:1 or 1:2 into 200 mM Tris, 
pH 8.0, 0.15 M NaCl. This concentration and pH of Tris was necessary to minimize 
PAI-1 precipitation as the solution pH passed through the pI of PAI-1, which is 6.6.  To 
remove any potentially precipitated protein after the dilution step, PAI-1 was centrifuged 
for 10 min and the supernatant transferred to a new microcentrifuge tube. This 
supernatant was applied to a PD-10 column equilibrated in 25 mM Tris, pH 7.4, 0.15 M 
NaCl, to exchange the buffer along with removing EDTA and any chelated metal ions. 
As described for BSA, protein-rich fractions were pooled, but PAI-1 was concentrated in 
a 0.5-ml Biomax Ultrafree centrifugal filtration device (Millipore). For Cu2+-binding 
studies with PAI-1, protein was prepared in unbuffered 0.15 M NaCl, with a pH below 
6.0. This solvent was used because all buffers tested either interacted with Cu2+, or failed 
to maintain PAI-1 in a soluble state. The protein was diluted 1:1 into 0.15 M NaCl, then 
centrifuged and applied to a PD-10 column equilibrated in 0.15 M NaCl, to exchange the 
buffer along with removing EDTA and any chelated metal ions. Protein-rich fractions 
were pooled and concentrated in a 0.5-ml Biomax Ultrafree centrifugal filtration device. 
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EPR Spectroscopy 
EPR experiments were performed with a Bruker EMX Spectrometer with an X-band 
microwave bridge, and WIN-EPR Acquisition Application software. Spectrum analysis 
was performed with Bruker WIN-EPR software. Instrument Settings: Instrument settings 
for Mn2+ studies were:  modulation frequency = 100 kHz, modulation amplitude = 4.0 G, 
time constant = 163.8 ms, sweep time = 41.9 or 83.9 s, receiver gain = 2.0 x 105, 
microwave power = 6.82 or 21.6 mW, microwave frequency = 9.88 GHz. Instrument 
setting for Cu2+-PAI-1 studies were: modulation frequency = 100 kHz, modulation 
amplitude = 4.9 G, time constant = 81.92 ms, sweep time = 5.24 s, receiver gain = 2.0 x 
105, microwave power = 21.6 mW, microwave frequency = 9.88 GHz.  Instrument 
settings for Cu2+-BSA studies were:  modulation frequency = 100 kHz, modulation 
amplitude = 4.9 G, time constant = 81.92 ms, sweep time = 10.8 s, receiver gain = 1.0 x 
105 - 2.0 x 105, microwave power = 5.90 - 21.6 mW, microwave frequency = 9.88 GHz.  
Data Acquisition: All EPR spectra were acquired at room temperature. Sample volumes 
ranged from 70 to 90 µl. For an individual experiment, the protein concentration was held 
constant, while the metal ion was titrated into separate samples.  For Cu2+-BSA 
experiments and all Mn2+ experiments, each sample was mixed and allowed to incubate 
at room temperature for 1 – 2 min. immediately prior to loading in the instrument and 
acquiring a spectrum. For Cu2+-PAI-1 experiments, because addition of Cu2+ often caused 
PAI-1 to precipitate, all samples were centrifuged to pellet any precipitated protein along 
with any bound Cu2+. The supernatant was transferred to a new sample tube, and each 
supernatant was loaded into the spectrometer for spectrum acquisition. Data analysis:  
Before analysis of Cu2+ sample spectra, a baseline spectrum for a sample containing only 
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buffer was subtracted from the spectra for samples containing only Cu2+; a spectrum for a 
sample containing only the protein was subtracted from the spectra for Cu2+-protein 
samples. For Mn2+ samples, spectra were analyzed without subtraction of a baseline, 
because the peak heights were much greater than the noise. 
Kinetic Assay for PAI-1 Activity and Stabilization by Vitronectin 
The stability of PAI-1 in the presence of metal ions, as well as PAI-1 in complex with 
vitronectin in the presence of metal ions, was assessed by the rate of conversion of PAI-1 
to latency when incubated at 37°C. The proportion of active PAI-1 was determined by its 
ability to inhibit trypsin, using a modification of the assay described by Gibson and 
Peterson [65]. PAI-1 at a final concentration of 6 µM in 50 mM Tris, pH 7.8, 15 mM 
NaCl, 0.1 mM EDTA, with or without an equimolar amount of vitronectin, was incubated 
at 37°C, with or without MgCl2; the final concentration of Mg2+ was either 0.2 mM or 2 
mM, relative to EDTA present. At various time points up to 3 h, an aliquot of the 6-µM 
PAI-1 was removed and diluted to 100 nM, in the same buffer except for a higher NaCl 
concentration (150 mM). Seventy microliters of this PAI-1 was mixed with an equal 
volume of 100 nM trypsin, prepared in 1 mM HCl. After a 5-min incubation at 37°C, 
residual trypsin activity was tested with addition of 60 µl of the PAI-1-trypsin mixture to 
940 µl S-2222 chromogenic substrate (Chromogenix), having a final concentration of 
100 µM, and also having been equilibrated to 37°C for 5 min. After 2 min at 37°C, the 
reaction was quenched by addition of 100 µl of 10% (w:v) SDS. The amount of substrate 
cleaved by trypsin was determined by reading the sample absorbance at 380 nm. The 
percent inhibition by PAI-1 was calculated relative to trypsin activity in the absence of 
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PAI-1. Percent inhibition was converted to PAI-1 activity, which was normalized to 
100% activity for time = 0 min of incubation of 6 µM PAI-1 at 37°C. 
Calculation of Standard Error 
Standard error was calculated using the following equation: 
standard error  = ×
n
1  sample standard deviation 
where 
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for  n = number of data points; xi = current data value; x = mean of data. 
 
Results 
Metal binding assessment by EPR 
Both vitronectin and PAI-1 were tested for binding to two paramagnetic metals, Mn2+ 
and Cu2+. A summary of the range of protein and metal concentrations tested is presented 
in Table 1. At room temperature, Mn2+ produces a useful EPR spectrum of six clearly 
defined peaks, even at low micromolar concentrations. The average of the six peak 
heights varies linearly with the concentration of free Mn2+ in the sample, for the range of 
concentrations used in these experiments.  Therefore,  this  characteristic  of the spectrum 
was used as a measure of free metal concentration in a sample.  An  example  of  an EPR 
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Table 1: Proteins and metals tested by EPR 
Protein Protein conc. 
range (µM) 






Vn 11-34 Mn2+ 5-50 0.25:1 to 4:1 No 
PAI-1 11-30 Mn2+ 5-50 0.16:1 to 4.4:1 No 
PAI-1-Vn 11-20 Mn2+ 5-50 0.25:1 to 4.4:1 No 
PAI-1 25-50 Cu2+ 50-500 2:1 to 11.5:1 Yes 
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spectrum for 20 µM Mn2+ is shown in Figure 8. Experimental conditions and instrument 
parameters for spectroscopy with Mn2+ are readily available in the literature. 
The spectrum for Cu2+ is less clearly defined, and most spectra in the literature were 
acquired with fairly high metal concentrations and at liquid nitrogen temperature (see e.g. 
[60] and [61]). Therefore, optimization of experimental conditions and instrument 
parameters was necessary before commencing room-temperature experiments on Cu2+ 
binding by our proteins. 
Three main areas of experimental conditions required optimization before collecting 
EPR data for Cu2+ binding: conditions for using EPR to measure Cu2+ concentration in 
solution at room temperature; the validity of using this technique to demonstrate Cu2+ 
binding by protein; and solubility of PAI-1 in a non-Cu2+-binding buffer and in the 
presence of Cu2+ itself. 
By trial and error, instrument settings and Cu  concentrations were identified that 
produced a useful room-temperature EPR spectrum. Subtraction of a background 
spectrum obtained for the buffer in the absence of metal, resulted in a spectrum with a 
pattern like that depicted in Figure 9. 
2+
Upon investigation of several features of the 
spectrum, one characteristic was identified to be most affected by Cu2+ concentration and 
also to vary linearly with concentration. The integral of the curve bounded by two certain 
points, indicated as a and b in Figure 9, was chosen as the characteristic to relate the 
measured spectrum to free Cu2+ concentration. The area under the curve is referred to as 
the peak intensity. A plot of intensity vs. concentration produced a standard curve like 























Figure 8: The EPR spectrum of Mn2+has six distinct peaks. 
An EPR spectrum of 20 µM Mn2+ in 25 mM Tris, pH 7.4, 0.15 M NaCl, was acquired at 
room temperature using microwave power of 6.82 mW and microwave frequency of 9.88 
GHz. The average of the peak heights, which increase linearly with increasing 



















Figure 9: EPR spectrum for 200 µM Cu2+. 
An EPR spectrum of 200 µM Cu2+ in 10 mM ACES, pH 7.0, was acquired at room 
temperature using microwave power of 6.79 mW and microwave frequency of 9.88 GHz. 
The integral of the curve between a and b  was found to increase linearly with free Cu2+ 
concentration, and was used as a measure of free Cu2+ in a sample. These conditions were 

































Figure 10: Standard curve for Cu2+ EPR peak intensity. 
EPR spectra of Cu2+ in 10 mM ACES, pH 7.0, were acquired at room temperature. Peak 
intensity was plotted against the concentration of Cu2+ in each sample. Each data point 
represents a single sample. The solid line represents a linear fit of the data. Error bars 
represent standard error. 
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BSA was used as a test protein to show that this technique is useful to demonstrate 
Cu2+ binding by protein. BSA is known to have multiple metal-binding sites [62], [66]. 
Cu2+ binding by BSA was demonstrated by a lower intensity due to free Cu2+ for BSA-
containing samples compared to Cu2+-only samples, as can be seen in Figure 11, for a 
high concentration of BSA and metal:protein ratios of 1:1 to 8:1. These results validated 
this technique for the study of Cu2+ binding by our proteins. 
The final obstacle to the use of this technique was lack of solubility of PAI-1 in a 
non-Cu2+-binding buffer and in the presence of Cu2+ itself.  Buffer is an important 
consideration when testing metal interactions with proteins, because some buffering 
components can interact with metal ions. This can change the availability of metals to 
interact with protein, and obscure measurement of the effect of metals on the protein. 
Phosphate, in particular, interacts strongly with metal ions; unfortunately, this is a 
preferred buffer when working with PAI-1. Therefore, another buffer had to be chosen 
for PAI-1-Cu2+ experiments. 
Five buffers were tested for PAI-1 solubility: ACES, MES, MOPS, HEPES, and 
unbuffered 0.15 M NaCl. A sixth buffer, Tris, was known to be acceptable for PAI-1 
preparation, but was questionable regarding its extent of interaction with Cu2+.  After 
testing Cu2+ in water (pH below 6) and  Cu2+ in Tris (pH 7.4), clear differences in the 
EPR spectra confirmed that this buffer interacts too strongly with Cu2+ to be an option for 
use. ACES is a good choice for Cu2+ binding experiments, and was used for all BSA-Cu2+ 
testing. However, upon dialysis into ACES, PAI-1 visibly precipitated. Dialysis into 
MES and MOPS also resulted in precipitated PAI-1.  PAI-1 was soluble in HEPES and in 



































Figure 11: Test for Cu2+-binding by BSA. 
EPR spectra of Cu2+, alone (open circles), or with 120 µM BSA (closed circles), in 10 
mM ACES, pH 7.0, were acquired at room temperature. Peak intensity due to free Cu2+ 
was plotted against the total concentration of Cu2+ in each sample. Metal binding is 
indicated by the lower intensity of the metal + protein samples. Each data point 
represents the average intensity of two samples. The solid lines represent linear fits of the 
data. Error bars represent standard error.  
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 precipitated, preventing collection of meaningful EPR data. Furthermore, while HEPES 
was believed not to interact strongly with Cu2+, the use of this buffer in subsequent 
experiments with Cu2+ and vitronectin showed that it does interact with Cu2+. This 
finding was confirmed by a recent report in the literature [67]. 
Various stabilizing agents added to Tris or HEPES also were tested for their potential 
to help maintain PAI-1 in a soluble form. However, polyethylene glycol (PEG) 8000 
(0.1%), 360 mM sorbitol, and 1M NaCl were all unsuccessful in maintaining PAI-1 
solubility.  
Because unbuffered 0.15 M NaCl was the only solvent that both kept PAI-1 in 
solution until Cu2+ addition and did not interfere with metal-binding measurements, it was 
selected for further testing. Each PAI-1 sample, prepared in 0.15 M NaCl with a pH 
adjusted to 6 or lower, was mixed with Cu2+ and allowed to incubate at room temperature 
for 1 – 2 min., before centrifugation to pellet any precipitated sample, which was visible 
in some instances. Although insoluble material was not observed in most samples, each 
was centrifuged to maintain consistent treatment of samples. The supernatant was 
transferred to a new sample tube, and each supernatant tested by EPR. This method 
resulted in a repeatable decrease in free Cu2+ that varied with the amount of Cu2+ added to 
the protein. Therefore, this method was used to assess Cu2+ binding by PAI-1. 
It should be noted that the Cu2+ spectrum used for the PAI-1 study is similar, but not 
identical, to that used for the BSA study, as previously shown in Figure 9. The difference 
is due to adjustments made to the instrument settings and data acquisition parameters, 
which permitted more straightforward data analysis. As can be seen from the example 


















Figure 12: EPR spectrum for 150 µM Cu2+ showing the height (h) used as a measure 
of concentration. 
An EPR spectrum of 150 µM Cu2+ in unbuffered 0.15 M NaCl with a pH below 6.0, was 
acquired at room temperature using microwave power of 21.6 mW and microwave 
frequency of 9.88 GHz. The peak height, h, was found to increase linearly with free Cu2+ 
concentration, and was used as a measure of free Cu2+ in a sample. These conditions were 
used for PAI-1-Cu2+ studies. 
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study has several peaks, one of which is considerably larger than the others. The peak-to-
trough height was found to increase linearly with the concentration of free metal in the 
sample, for the range of concentrations used in these experiments. Therefore, this 
characteristic of the spectrum was used as a measure of free metal concentration in a 
sample. A comparison of several spectra illustrating the increase in peak height with 
increasing concentration is presented in Figure 13. 
As shown by the differing heights of the EPR spectra depicted in Figures 14 and 15, 
PAI-1 binds Cu2+. The data set for a range of Cu2+ concentrations is plotted in Figure 16. 
Scatchard analysis of the binding data allows calculation of an approximate Kd equal to 
or below 15 µM, and a stoichiometry of at least 5:1 metal:protein (Figure 17). However, 
this method is not sensitive enough for complete characterization of the binding 
interaction (i.e., definitive determination of affinity and total number of binding sites, for 
both the tighter and the weaker interactions); for Cu2+ concentrations below 100 µM, the 
signal is not clearly distinguishable from the noise. Data from samples containing less 
than 100 µM Cu2+ would be needed for complete characterization of this binding 
interaction. 
Vitronectin was shown not to bind Mn2+, when tested over a metal:protein range from 
0.25:1 to 1:1 (see Figure 18). Substoichiometric metal concentrations were used because 
this condition is necessary to detect weak binding. Other experiments, using as high as a 
4:1 metal:protein ratio, also failed to indicate Mn2+ binding by vitronectin (data not 
shown). Similarly, PAI-1 and the complex of PAI-1-vitronectin were shown not to bind 
Mn2+ (see Figures 19 and 20).  Higher metal concentrations also failed to indicate binding 




















Figure 13: Overlaid EPR spectra for 75 to 300 µM Cu2+. 
EPR spectra of Cu2+ in unbuffered 0.15 M NaCl with a pH below 6.0, were acquired at 
room temperature using microwave power of 21.6 mW and microwave frequency of 9.88 
GHz. Cu2+ concentrations represented are: 75 µM (thick, solid line); 100 µM (thick, 
































Figure 14: EPR spectra for (A) 100 µM and (B) 150 µM Cu2+, with and without 
25 µM PAI-1. 
EPR spectra of Cu2+ alone (thin line) or with 25 µM PAI-1 (thick line) in unbuffered 
0.15 M NaCl with a pH below 6.0, were acquired at room temperature using microwave 
power of 21.6 mW and microwave frequency of 9.88 GHz. Binding is indicated by the 





























Figure 15: EPR spectra for (A) 200 µM and (B) 300  µM Cu2+, with and without 
25 µM PAI-1. 
EPR spectra of Cu2+ alone (thin line) or with 25 µM PAI-1 (thick line) in unbuffered 
0.15 M NaCl with a pH below 6.0, were acquired at room temperature using microwave 
power of 21.6 mW and microwave frequency of 9.88 GHz. Binding is indicated by the 


































Figure 16: Test for Cu2+-binding by 25 µM PAI-1. 
EPR spectra of Cu2+ alone (open circles) or with 25 µM PAI-1 (closed circles), in 
unbuffered 0.15 M NaCl with a pH below 6.0, were acquired at room temperature. Peak 
intensity due to free Cu2+ was plotted against the total concentration of Cu2+ in each 
sample. Metal binding is indicated by the lower intensity of the metal + protein samples. 
Each data point represents the average intensity of two samples. The thin lines represent 
linear fits of the data, while the thick line estimates the tighter binding of the suspected 




























Figure 17: Scatchard plot for Cu2+-binding by 25 µM PAI-1. 
[b] and [f] represent concentration of bound Cu2+ and free Cu2+, respectively. Line 
represents linear fit of data. The negative slope of the fit line, 15 µM, is an estimate of  
the Kd for PAI-1- Cu2+. The x-intercept, 5.4, is an estimate of the number of binding sites 





































Figure 18: Test for Mn2+-binding by 34 µM Vn. 
EPR spectra of Mn2+ alone (open circles) or with 34 µM Vn (closed circles), in 25 mM 
Tris, pH 7.4, 0.15 M NaCl, were acquired at room temperature. Peak intensity due to free 
Mn2+ was plotted against the total concentration of Mn2+ in each sample. The intensity 
due to free Mn2+ does not decrease in the presence of protein, indicating no metal bound 
by the protein. Each data point represents the average intensity of two samples. Lines 
represent linear fits of the data for Mn2+ alone (solid) or Mn2+ + Vn (dashed). Error bars 


































Figure 19: Test for Mn2+-binding by 30 µM PAI-1. 
EPR spectra of Mn2+ alone (open circles) or with 30 µM PAI-1 (closed circles), in 25 
mM Tris, pH 7.4, 0.15 M NaCl, were acquired at room temperature. Peak intensity due to 
free Mn2+ was plotted against the total concentration of Mn2+ in each sample. The 
intensity due to free Mn2+ does not decrease in the presence of protein, indicating no 
metal bound by the protein. Each data point represents the average intensity of two 
samples. Lines represent linear fits of the data for Mn2+ alone (solid) or Mn2+ + PAI-1 



































Figure 20: Test for Mn2+-binding by 20 µM PAI-1-Vn. 
EPR spectra of Mn2+ alone (open circles) or with 20 µM PAI-1-Vn (closed circles), in 25 
mM Tris, pH 7.4, 0.15 M NaCl, were acquired at room temperature. Peak intensity due to 
free Mn2+ was plotted against the total concentration of Mn2+ in each sample. The 
intensity due to free Mn2+ does not decrease in the presence of protein, indicating no 
metal bound by the protein. Each data point represents the average intensity of two 
samples. Lines represent linear fits of the data for Mn2+ alone (solid) or Mn2+ + PAI-1-Vn 
(dashed). Error bars represent standard error. 
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Mg2+ has no measurable effect on PAI-1 activity or on stabilization by vitronectin 
A diagram presenting the procedure for the kinetic assay used to assess PAI-1 activity 
is shown in Figure 21. Kinetic testing revealed that, under the conditions of the assay, 
Mg2+ has no measurable effect on PAI-1 activity or on PAI-1 stabilization by vitronectin. 
PAI-1 exhibited the same amount of inhibitory activity towards trypsin, and lost this 
activity at a similar rate, in the presence and absence of Mg2+. Furthermore, vitronectin 
stabilized PAI-1 for the same length of time in the presence and absence of Mg2+. 
Attempts to test the effect of Ca2+ failed due to technical difficulties, including 
intermittent precipitation of the sample upon incubation with Ca2+, and poor repeatability 
of results. 
Considerable optimization of experimental conditions was necessary before using this 
assay to determine the effect of Mg2+ on our proteins. The initial step towards optimizing 
the assay was determining appropriate concentrations of substrate and trypsin to use, to 
give adequate end absorbance with room for detecting a decrease upon PAI-1 inhibition. 
Early problems were two-fold: poor repeatability, despite careful control of conditions; 
and low final absorbance, despite testing a range of substrate concentrations, including 
concentrations much higher than recommended by the manufacturer. 
The low final absorbance was traced to the trypsin supply. The original choice for the 
enzyme was Promega sequencing-grade trypsin; however, although a higher grade, 
Promega trypsin is not as active against the S-2222 substrate as is Sigma trypsin. An 
additional modest increase in absorbance was realized by determining that the actual peak 















Figure 21: Kinetic assay to test PAI-1 activity. 
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group. Changing the trypsin source and the wavelength for absorbance measurement 
resulted in a higher final absorbance from the assay, allowing maximum opportunity for 
detecting a decrease in absorbance upon addition of PAI-1 to the assay. 
The poor repeatability was traced to self-degradation of substrate in the solution 
conditions  recommended  by the manufacturer  (lyophilized  stock  dissolved in water or 
buffer, stored at 4°C). Even in the absence of trypsin, a slow increase in absorbance could 
be measured for a solution of substrate in real time. A substrate solution made in 1mM 
HCl was found to be stable; aliquots frozen at -20°C permitted long-term storage of 
substrate stock in 1mM HCl. 
We needed to identify conditions such that PAI-1 was even less stable than under 
physiological conditions. This would permit monitoring PAI-1 activity, when stabilized 
by vitronectin, over an increased time span. A low-salt buffer containing 15 mM NaCl in 
Tris, instead of physiological, 150 mM NaCl, was used for PAI-1 at a concentration of 6 
µM. These conditions resulted in PAI-1 being stable at 4°C for a suitably long time, 
while losing activity rapidly at 37°C. It should be noted that PAI-1 was diluted into Tris 
with 150 mM salt before incubation with trypsin, and the actual cleavage reaction of the 
assay was also performed in Tris with 150 mM salt. 
Initial experiments were performed with the reaction occurring in a temperature-
controlled cell, which allowed monitoring of the rate of reaction at 37°C. This method 
was used to confirm the linear range of the reaction. Determination of the time-frame of 
linearity allowed using an end-point measurement of absorbance, quenching the reaction 
at a given time within the linear range of the reaction, and then reading the absorbance. 
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This allowed duplicate reactions to be run simultaneously. Several reagents were tested to 
find a suitable one that stopped the reaction without diluting the sample excessively, 
changing the final absorbance excessively, or shifting the peak wavelength. Reagents that 
were tested include NaOH, HCl, and SDS. A two-minute end point was chosen, and the 
reaction was quenched by addition of 100 µl of SDS (10%, w:v). 
The results of the kinetic assays are shown graphically in Figures 22, 23, and 24. 
Comparison of the data sets in Figure 22 shows that the rate of loss of PAI-1 inhibitory 
activity is the same in the presence and in the absence of Mg2+. Likewise, as comparison 
of the data sets in Figure 23 shows, the ability of vitronectin to stabilize PAI-1 is the 
same in the presence and in the absence of Mg2+. A comparison of the stability of PAI-1 
in the presence and absence of vitronectin, confirming the characteristic stabilizing effect 
of vitronectin towards PAI-1, is shown in Figure 24. Analysis of these results together 
demonstrates that, under the conditions of this assay, Mg2+ has no measurable effect on 
PAI-1 activity or on PAI-1 stabilization by vitronectin. 
 
Discussion and Future Directions 
Metal-binding studies 
We have shown that EPR is not an effective method for quantifying metal binding by 
PAI-1 and vitronectin, although it is somewhat effective for qualifying binding, i.e., 
determining whether binding exists. As a means of studying the solution interaction 



























Figure 22: Kinetic assay to measure activity of PAI-1 +/- Mg2+. 
PAI-1 at a final concentration of 6 µM in 50 mM Tris, pH 7.8, 15 mM NaCl, 0.1 mM 
EDTA, was incubated at 37°C, either alone (open circles) or with 2 mM MgCl2 (relative 
to EDTA; closed circles). At various time points, an aliquot of PAI-1 was diluted to 100 
nM, in the same buffer except for a higher NaCl concentration (150 mM), and mixed 
with an equimolar amount of trypsin. After a 5-min incubation at 37°C, residual trypsin 
activity was measured using S-2222 chromogenic substrate, as described in Materials 
and Methods. Percent inhibition of trypsin by PAI-1 was calculated relative to trypsin 
activity in the absence of PAI-1. Percent inhibition was converted to PAI-1 activity, 
which was normalized to 100% activity for time = 0 min of incubation of 6 µM PAI-1 at 
37°C. Each data point represents the average of two samples. Error bars represent 

























Figure 23: Kinetic assay to measure activity of PAI-1-Vn +/- Mg2+. 
Equimolar PAI-1-Vn complex at a final concentration of 6 µM in 50 mM Tris, pH 7.8, 15 
mM NaCl, 0.1 mM EDTA, was incubated at 37°C, either alone (open circles) or with 2 
mM MgCl2 (relative to EDTA; closed circles). At various time points, an aliquot of 
PAI-1-Vn was diluted to 100 nM, in the same buffer except for a higher NaCl 
concentration (150 mM), and mixed with an equimolar amount of trypsin. After a 5-min 
incubation at 37°C, residual trypsin activity was measured using S-2222 chromogenic 
substrate, as described in Materials and Methods. Percent inhibition of trypsin by PAI-1 
was calculated relative to trypsin activity in the absence of PAI-1. Percent inhibition was 
converted to PAI-1 activity, which was normalized to 100% activity for time = 0 min of 
incubation of 6 µM PAI-1-Vn at 37°C. Each data point represents the average of two 


























Figure 24: Kinetic assay to measure activity of PAI-1 +/- Vn. 
PAI-1 alone (open circles), or equimolar PAI-1-Vn complex (closed circles),  at a final 
concentration of 6 µM in 50 mM Tris, pH 7.8, 15 mM NaCl, 0.1 mM EDTA, was 
incubated at 37°C. At various time points, an aliquot of PAI-1 or PAI-1-Vn was diluted 
to 100 nM, in the same buffer except for a higher NaCl concentration (150 mM), and 
mixed with an equimolar amount of trypsin. After a 5-min incubation at 37°C, residual 
trypsin activity was measured using S-2222 chromogenic substrate, as described in 
Materials and Methods. Percent inhibition of trypsin by PAI-1 was calculated relative to 
trypsin activity in the absence of PAI-1. Percent inhibition was converted to PAI-1 
activity, which was normalized to 100% activity for time = 0 min of incubation of 6 µM  
PAI-1 or PAI-1-Vn at 37°C. Each data point represents the average of two samples. 
Error bars represent standard error.  
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It was found that PAI-1-Cu2+ binding is clearly detectable by EPR, but the method is 
not sensitive enough for determination of affinity and the number of binding sites; for 
Cu2+ concentrations below 100 µM, the signal is not clearly distinguishable from the 
noise. However, Scatchard analysis was performed for data from samples having at least 
100 µM Cu2+, allowing estimation of a maximum Kd equal to 15 µM, which  indicates  a 
reasonably tight affinity for at least one set of metal-binding sites on PAI-1. Scatchard 
analysis also allowed estimation of at least five sites having this maximum Kd. It is 
suspected that one or two sites with a lower Kd also exist, but this method is not 
amenable to characterization of such sites. 
Another difficulty encountered in the study of Cu2+ binding is that buffer choices for 
Cu2+ measurements are few, because many standard buffers used with both of our 
proteins bind Cu2+ themselves. For this reason, PAI-1 experiments were done in water 
without buffer, with only NaCl. One vitronectin-Cu2+ experiment was performed, but its 
strange results led to further testing of potential Cu2+ binding by the buffer used 
(HEPES), revealing that the buffer did bind the metal in the experiment, such that Cu2+ 
binding by vitronectin could not be assessed. It could be worthwhile to try additional 
vitronectin-Cu2+ EPR experiments if a suitable buffer can be found, testing the 0.15 M 
NaCl solution as a first option. Even if quantitative conclusions are not possible, 
qualitative conclusions may be attainable.  
Lack of binding detection between vitronectin or PAI-1 and the second paramagnetic 
metal tested, Mn2+, may be due to such a weak affinity that it is too low to be measured 
by this method. Detection of weak affinity requires substoichiometric M:P samples, but 
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for such samples to be useful, either the metal must have a detectable EPR spectrum at 
low concentrations, or the protein must be stable at high concentrations. The tendency of 
our two proteins to aggregate at even moderate concentrations limits the highest 
concentration of protein possible for samples. Combined with the lower limit on 
detectable Mn2+, these restrictions greatly narrow the range of M:P ratios that may be 
measured. Although Mn2+ has a useful EPR spectrum at low micromolar concentrations 
(below 10 µM), these concentrations are not very low in terms of our proteins. Only a 
narrow range of substoichiometric M:P samples are available for testing. 
Based on our knowledge of specific but weak binding of PAI-1 to immobilized Mn2+, 
the lack of binding detection between Mn2+and PAI-1 in solution was not entirely 
unexpected. The “effective concentration” of an immobilized ligand is greater than the 
actual concentration of the same amount of ligand in solution.  This is due to the higher 
likelihood that the binding molecule will encounter an immobilized ligand compared to a 
ligand in solution. Therefore, although Mn2+ binding by PAI-1 is indicated by the IMAC 
method, but is not indicated by EPR, these results are not contradictory. 
For future work, an alternative technique to use for metal-binding studies is NMR. 
For both PAI-1 and the SMB domain, spectra could be acquired in the presence and in 
the absence of metals. Any peak shifts or other changes in the spectra would indicate 
metal binding. For the SMB domain, the existence of a solved NMR structure for this 
peptide [6] would aid in identifying peak shifts or other changes resulting from metal ions 
binding. A limitation of this method is that full-length vitronectin, at 62 kDa, is too large 
for NMR studies. However, an advantage of this method is that metal choices are not 
limited to those that are paramagnetic, as was a requirement for EPR experiments. Other 
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metals shown to bind PAI-1 by IMAC, including Co2+ (which is paramagnetic, but 
requires liquid nitrogen temperature for EPR study), Ni2+, and Zn2+, would be good 
candidates for metal-binding studies by NMR. 
Absence of Mg2+ effect on PAI-1 activity and on stabilization by vitronectin 
A kinetic assay was used to study the effect of metals on PAI-1 activity and 
stabilization by vitronectin. Although clearly showing no detectable effect of Mg2+, these 
results are limited in two ways: they reflect only a single method of testing, and only a 
single metal was tested for its effect. Both Mg2+ and Ca2+ were initially chosen for 
investigation due to their presence and influence in our integrin-binding buffer. Because 
it is vitronectin which binds directly to integrins in the form of the vitronectin-PAI-1 
complex, it was expected that these metals might have an effect, through binding to 
vitronectin, on stabilization of PAI-1. However, Mg2+ was shown to have no effect, and 
difficulty maintaining Ca2+ in solution when mixed with the PAI-1 sample prevented 
testing of the effect of this metal in the kinetic assay. It could be worthwhile to attempt 
further optimization of conditions that permit assaying the effect of Ca2+ on PAI-1 
activity or stabilization by vitronectin. In addition, based on the results of PAI-1 binding 
studies with Cu2+, it would be interesting to study the effect of Cu2+ on the activity of the 
protein. Other metals shown to bind PAI-1 by IMAC, including Ni2+, Zn2+ and Co2+, 
could be tested as well. 
An alternative method of assessing a change in PAI-1 activity and stability is the tPA 
assay, described in Chapter 3 for testing D-14-1B PAI-1 activity. This assay is essentially 
the same as the assay with trypsin, but the serine protease (tPA) is a cognate PAI-1 target. 
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It is possible that metals, especially one that binds well, like Cu2+, might have an effect 










As mentioned in Chapter 1, high-resolution structural information for vitronectin is 
lacking, in part due to some attributes that make vitronectin unsuited for the more 
common techniques of three-dimensional structural determination, i.e., NMR and x-ray 
crystallography. At 62-kDa, it is not a likely candidate for NMR studies; although two 
solution structures for the 5-kDa SMB domain of vitronectin have been solved by NMR 
[6, 7], this represents only a small portion of the entire protein. Glycosylations of 
vitronectin, along with its tendency to self-multimerize, hinder crystallization of the 
protein. A crystal structure has been solved for only the SMB domain, in complex with 
PAI-1 [8]. 
Other approaches have been used to provide additional structural information for 
vitronectin. Computational models from threading have been published for three main 
domains of vitronectin: the SMB domain; nearly 200 residues of the central domain; and 
the C-terminal domain, including the heparin binding region [10]. But these are only 
predictions and again cover only discrete regions of vitronectin, separate from the 
complete polypeptide. Three-dimensional structural information for the entirety of 
vitronectin is limited to a low-resolution model of the protein from SAXS [9]. Clearly, 
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alternative techniques must be employed to elucidate further structural details of 
vitronectin. 
One alternative technique that our laboratory plans to apply to vitronectin and the Vn-
PAI-1 complex is small-angle neutron scattering (SANS). Although such a technique is 
outside the scope of the work for this thesis, this work has provided one of the deuterated 
reagents, D-PAI-1, necessary to carry out these experiments. 
The method of SANS, which relies on the ability of certain atomic nuclei to scatter 
incident neutrons, can provide the basic shape and size of a molecule in solution, with a 
resolution range of 10 – 1000 Å. Hydrogen and deuterium nuclei scatter neutrons 
differently, resulting in different scattering length densities. This difference directly 
affects the intensity of the detected, scattered neutron beam. In the two-phase system of a 
particle in a solvent, the difference in the scattering length densities of particle and 
solvent is referred to as “contrast.” The scattering length density of the solvent can be 
varied by including D2O, and changing the D2O/H2O ratio. Thus, the contrast can be 
adjusted to provide a more intense scattered neutron beam from the particle relative to 
that from the solvent, and the data collected can be used to produce a three-dimensional 
model of the particle. 
Whereas SAXS also can provide size and shape information of about the same 
resolution, an advantage of SANS can be realized in analysis of a complex of different 
molecules, such as higher-order Vn-PAI-1 complexes. Using SANS, if one molecule is 
perdeuterated and the other is protonated, in addition to adjusting the solvent D2O/H2O 
ratio so that the entire complex can be differentiated from the solvent, the D2O/H2O ratio 
can be adjusted to allow only the protonated or only the deuterated species to be 
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differentiated from the solvent. This can provide information about the relative positions 
of each type of molecule in the complex. For Vn-PAI-1, SAXS can be used to determine 
the outer envelope of the complex, as well as the radius of gyration, and this information 
can aid in analysis of the SANS data. Because hydrogen and deuterium scatter x-rays the 
same, both proteins can be protonated for a SAXS experiment. Although vitronectin and 
PAI-1 in the complex analyzed by SAXS will be indistinguishable from each other, 
combining information from SAXS and SANS can reveal the locations of each protein 
relative to the other. Furthermore, comparing the shape of monomeric vitronectin 
obtained by SANS with the shape of vitronectin in complex with PAI-1 can provide 
information about conformational changes in vitronectin upon binding PAI-1. Similar  
changes are thought to occur in several other situations for vitronectin, including ECM 
deposition [68] and complex formation with thrombin-antithrombin [52]. Such 
conformational information may be widely applicable. 
Since vitronectin is typically isolated from human plasma, and therefore cannot be 
deuterated, the recombinant PAI-1 must be deuterated for SANS experiments involving 
the complex. A recombinant bacterial expression system for PAI-1 was adapted to 
produce perdeuterated 14-1B PAI-1 (D-14-1B PAI-1), using a deuterated rich growth 
medium. D-14-1B PAI-1 was purified, characterized and assayed for activity. In addition, 
conditions were determined under which vitronectin, PAI-1, and the Vn-PAI-1 complex, 
are monodisperse and free from aggregation in solution, two aspects which are crucial to 
meaningful scattering measurements. The methods developed have already been used by 
others in our laboratory to prepare D-PAI-1 used in an initial set of SANS experiments. 
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D-PAI-1 can be used in other future work requiring deuterated protein – not only with 
additional SANS experiments, but also with NMR. 
  
Materials and Methods 
Materials 
Plasmid DNA coding for wtPAI-1 (contained in the pET24d vector) and 14-1B PAI-1 
(contained in the pEX vector) was a gift from Grant Blouse (Henry Ford Health System). 
Competent Escherichia coli (E. coli) cells, strain BL21(DE3) pLysS, were purchased 
from Novagen. Minimal medium with M9 salts was prepared according to Maniatis [69], 
with the additional components, MgSO4, CaCl2, biotin, and GIBCO MEM Vitamin 
solution (GIBCO). Celtone complete media, both unlabeled and deuterated, were from 
Spectra Stable Isotopes; Silantes rich media, both unlabeled and OD21 D (deuterated), 
were from Silantes GmbH. tPA and monoclonal antibody to PAI-1 were from Molecular 
Innovations; polyclonal anti-PAI-1 serum was a gift from Dr. Tom Podor. Peroxidase-
linked anti-mouse antibody and anti-rabbit antibody were from Vector Labs. 
Expression and Purification of Recombinant PAI-1 (wild-type and 14-1B mutant) 
Plasmid DNA coding for wtPAI-1 or 14-1B PAI-1 was transformed into competent 
E.coli cells, strain BL21(DE3) pLysS, which were plated on agar with appropriate 
antibiotics: 30 µg/ml chloramphenicol and either 40 µg/ml kanamycin (pET24d) or 50 
µg/ml ampicillin (pEX). After overnight growth at 37°C, transformants were grown in 
Luria broth (LB) at 30 or 37°C to mid-log phase, when PAI-1 expression was induced 
                                                 
1 “OD2 D” is the name of rich media produced by Silantes. “OD2” indicates the level of cell density 
typically achieved, as measured by optical density. 
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with addition of isopropylthiogalactoside (IPTG) to 1.0 mM. After 3 to 6 hours, cells 
were harvested by centrifugation, resuspended in lysis buffer (50 mM Tris, pH 6.6, 
containing 100 mM NaCl and 1 mM EDTA), and lysed with three freeze-thaw cycles. 
The lysed cell suspension was centrifuged to pellet the cellular debris and insoluble 
proteins. The supernatant was diluted by 1/3 with Buffer A (50-mM potassium phosphate 
buffer, pH 6.6, containing 1 mM EDTA), followed by addition of 65% ammonium 
sulfate to precipitate the proteins. This suspension was centrifuged to pellet the proteins, 
and the pellet was resuspended in Buffer SB (50-mM potassium phosphate buffer, pH 
6.6, containing 80 mM ammonium sulfate and 1 mM EDTA), and dialyzed against this 
buffer. The PAI-1 protein was isolated from this solution by successive column 
chromatography steps using heparin sepharose, phenyl sepharose, and sulfopropyl (SP) 
sepharose (Amersham Biosciences). The heparin sepharose column was equilibrated and 
washed (after sample loading) in Buffer SB; bound protein was eluted with a linear 
gradient to Buffer B (50-mM potassium phosphate buffer, pH 6.6, containing 1.15 M 
ammonium sulfate and 1 mM EDTA). PAI-1-containing fractions were pooled, the 
ammounium sulfate concentration was adjusted to approximately 1.15 M, and the sample 
was loaded on the phenyl sepharose column, which was equilibrated and washed in 
Buffer B, and eluted in a linear, reverse salt gradient to Buffer A. PAI-1-rich fractions 
were pooled and precipitated in 65% ammonium sulfate, resuspended in Buffer A, and 
loaded on the SP sepharose column, which had been charged with Buffer B, then 
equilibrated in Buffer SB.  Following a wash in Buffer SB, PAI-1 was eluted in a linear 
gradient to Buffer C (50-mM potassium phosphate buffer, pH 6.6, containing 0.5 M 
ammonium sulfate and 1 mM EDTA). Protein purity was assessed by SDS-PAGE and 
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Western blot. PAI-1-rich fractions were pooled and dialyzed into storage buffer (5 mM 
sodium phosphate, pH 6.25, 0.35 M NaCl, 1 mM EDTA). Purified PAI-1 was stored at 
-80°C. 
Expression of Deuterated 14-1B PAI-1 
Transformation and competent cell growth were as described above for protonated 
14-1B PAI-1. After overnight growth at 37°C, transformants were grown in Silantes OD2 
D deuterated rich media at 30 or 37°C to mid-log phase, when 14-1B PAI-1 expression 
was induced with addition of IPTG to 1.0 mM. Expression was allowed to continue for 
6 h. Cell harvest and lysing, as well as protein purification, were as described above for 
protonated PAI-1. 
SDS-PAGE and Western Blotting 
Proteins were electrophoresed on a 10% polyacrylamide SDS gel. Protein bands were 
visualized either by staining with Coomassie blue followed by destaining with glacial 
acetic acid and methanol, or by staining with GelCode Blue Stain Reagent (Pierce) 
followed by destaining with water. For Western blotting, after proteins were 
electrophoresed as above, they were transferred to a nitrocellulose membrane using a 
Semi-dry Transfer Cell (BioRad) in buffer consisting of 0.35 M glycine, 25 mM Tris, and 
20% (v:v) methanol. The membrane was blocked against nonspecific antibody binding by 
incubation in 10% (w:v) nonfat dry milk in PBS. The membrane was washed three times 
in PBS containing 0.05% (v:v) Tween-20. The membrane was probed for PAI-1 by 
incubation in 2% nonfat dry milk in PBS containing an appropriately diluted murine 
monoclonal antibody to PAI-1 (1:25,000) or polyclonal anti-PAI-1 rabbit serum 
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(1:10,000), then washed three times as before. A horseradish peroxidase-linked anti-
mouse antibody or anti-rabbit antibody, as appropriate, was applied as a 1:2,500 dilution 
in 2% nonfat dry milk in PBS. The membrane was washed as before, then the proteins 
were visualized by development in PBS containing 3 mg/ml 4-chloronaphthol in 
methanol and 0.05% (v:v) 30% H2O2. 
tPA Activity Assay 
Purified PAI-1 activity was assessed by its ability to inhibit tPA activity. An aliquot 
(10-20 µl) of PAI-1 was mixed with tPA having a final concentration of 0.2 µM in 25mM 
HEPES, pH 7.4, 0.135M NaCl, 1 mM EDTA. After a 10-min. incubation at 37°C, 
residual tPA activity was tested with addition of 100 µl of the PAI-1-tPA mixture to 
900 µl Spectrozyme-tPA chromogenic substrate (American Diagnostica) having a final 
concentration of 90 µM. After 5 min. at 37°C, the reaction was quenched with acetic 
acid. The amount of cleaved substrate was determined by reading the sample absorbance 
at 405 nm. 
PAI-1-tPA Binding Assay 
To test PAI-1 for the ability to form a SDS-stable complex with tPA, the two proteins 
were mixed in a 1:2 PAI-1:tPA ratio and incubated at room temperature for 15 min. The 
binding reaction was quenched with addition of 0.1M HCl. Non-reducing gel-loading 
buffer was added, without boiling, followed by addition of 1M NaOH to return pH to 
basic. Fifty-microliter samples were loaded on a 10% SDS-polyacrylamide gel and 
electrophoresed, followed by staining with Coomassie blue. 
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Dynamic Light Scattering 
Dynamic light scattering experiments were performed at Oak Ridge National 
Laboratory with a Wyatt Technology instrument, using a source wavelength of 690 nm. 
Vitronectin and PAI-1 were tested individually and as a complex, in phosphate-buffered 
saline (PBS) at pH 7.4, with either a physiological concentration of NaCl (0.15 M) or a 
high-salt concentration (0.31 M). To determine if high-molecular weight aggregates were 
present in the proteins, PAI-1 (molecular weight 43 kDa) was either filtered through a 
100-kDa filter or unfiltered, and vitronectin (molecular weight 62 kDa) was filtered 
through either a 100-kDa filter, a 300-kDa filter, or no filter. For the complex, PAI-1 and 
vitronectin were added in equimolar concentrations, to give a total protein concentration 
of 0.7 mg/ml. 
 
Results and Discussion 
PAI-1 Expression and Purification 
Active, deuterated 14-1B PAI-1 was successfully expressed in Silantes deuterated rich 
medium. The strategy for identifying a suitable growth medium was to compare growth 
and expression in three types of unlabeled media, followed by assessing growth and 
expression in deuterium-labeled media. The three types of unlabeled media were: 
minimal medium with M9 salts, Celtone complete medium, and Silantes rich medium. 
Compared to cell growth in LB, growth in unlabeled Celtone and Silantes was 
acceptable, while growth in minimal medium was very low. Figure 25 shows a 
























Figure 25: Growth curves for E. coli in unlabeled media. 
Unlabeled versions of two potential deuteration media were compared for support of E. 
coli growth and PAI-1 expression. Growth and expression, both at 37°C, were in either 
LB (circles), Silantes unlabelled rich medium (squares), or M9 minimal medium, 
supplemented as described in Materials and Methods (diamonds). Because growth in 
Silantes unlabeled medium was superior to growth in unlabeled M9 medium, Silantes 
medium was chosen for expression of labeled (deuterated) PAI-1. Each data point 





media. SDS gels and Western blots of cell lysates, after induction of PAI-1 expression, 
were used to assess PAI-1 expression. Expression levels in unlabeled M9 medium were 
deemed too low to expect useful protein expression in deuterated M9 medium; therefore 
this option was eliminated from consideration. 
The protocol for Celtone growth requires adaptation of bacteria to gradually 
increasing levels of deuterium over five days, while fully deuterated Silantes medium can 
be inoculated directly with a small start-up culture after several hours of growth. Cells in 
Celtone failed to express PAI-1 protein. However, expression in Silantes was comparable 
to that in LB. Therefore, Silantes deuterated rich medium was chosen for growth and 
expression of D-PAI-1. The PAI-1 purification procedure was tested with 2-liter batches 
of LB-expressed protein, before 2-liter production of labeled Silantes-produced protein. 
Mass spectrometry analysis of D-PAI-1 produced in Silantes showed the protein to be 
approximately 86% deuterated, well above the minimum level of 70% deuterium 
incorporation required for SANS experiments. 
PAI-1 Activity Testing 
To test D-14-1B PAI-1 for activity, two assays were performed: one to test binding to 
its cognate serine protease, tPA; and one to test inhibitory activity toward tPA. In the tPA 
binding assay, PAI-1 is incubated with excess tPA, and the sample is electrophoresed on 
a polyacrylamide gel. Active PAI-1 forms an SDS-stable complex with tPA (the acyl-
enzyme intermediate complex, which PAI-1 RCL insertion prevents from resolution by 
the protease), detectable by its migration position on the gel. D-14-1B-PAI-1 was shown 
to bind tPA, with very little unbound inhibitor remaining, indicating most of the isolated 





Figure 26: D-14-1B PAI-1 binding of tPA is comparable to H-14-1B PAI-1 binding 
of tPA. 
PAI-1 was tested for the ability to form an SDS-stable complex with tPA, by mixing in a 
1:2 PAI-1:tPA ratio and incubating at room temperature for 15 min. The binding reaction 
was quenched with addition of 0.1M HCl, and non-reducing gel-loading buffer was 
added, without boiling, followed by addition of 1M NaOH to return pH to basic. Fifty-
microliter samples were analyzed by 10% SDS-polyacrylamide gel and electrophoresed, 
followed by staining with Coomassie blue. Presence of SDS-stable PAI-1-tPA complex 
indicates active PAI-1. Lane 1: Molecular weight standards; lane 2: D-14-1B PAI-1, 
sample #1; lane 3: tPA + D-14-1B PAI-1, sample #1; lane 4: tPA control; lane 6: D-14-
1B PAI-1, sample #2; lane 7: tPA + D-14-1B PAI-1, sample #2; lane 9: commercial 14-
1B PAI-1 control; lane 10: tPA + commercial 14-1B PAI-1 control. 
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The tPA inhibition assay uses a chromogenic tPA substrate. When the substrate is 
cleaved by tPA, its absorbance peak shifts; this can be measured spectrophotometrically. 
Active PAI-1 binds to tPA and inhibits cleavage of substrate, resulting in less color 
development. Both protonated and deuterated 14-1B PAI-1 were confirmed to be active 
by this assay, with absorbance by the cleaved substrate giving a clear concentration-
dependent response to increasing PAI-1 concentration (Figure 27). 
Confirmation of protein monodispersity 
Crucial for meaningful neutron scattering experiments are monodisperse samples free 
from aggregates. Experimental conditions giving monodisperse, non-aggregated PAI-1, 
as well as vitronectin and Vn-PAI-1 complexes, were determined. To characterize the 
behavior of the proteins under various buffer and preparation conditions, dynamic light 
scattering (DLS) was used. Also known as quasi-elastic scattering, DLS measures time-
dependent fluctuations in the scattered light. It gives a weighted average of the 
hydrodynamic radius (Rh) of macromolecules or particles in solution. A single Rh value 
that is reasonable for the macromolecular species of interest indicates the molecules to be 
monodisperse and not aggregated. For a 1:1 molar ratio of PAI-1 to vitronectin, at a total 
protein concentration of 0.7 mg/ml, acceptable conditions for monodispersity and lack of 
aggregation were found with buffer having 150 mM NaCl; PAI-1 filtered through a 100-
kDa filter; and vitronectin filtered through a 300-kDa filter. These conditions have since 
been used by others in our laboratory for SANS experiments, and should be suitable for 























Figure 27: Activity of D-14-1B PAI-1 is comparable to activity of H-PAI-1. 
Purified PAI-1 was assessed by its ability to inhibit tPA activity. Aliquots of increasing 
concentration of H-14-1B PAI-1 (squares) or D-14-1B PAI-1 (circles) were mixed with 
tPA having a final concentration of 0.2 µM in 25mM HEPES, pH 7.4, 0.135M NaCl, 
1 mM EDTA. After a 10-min incubation at 37°C, residual tPA activity was measured 
using Spectrozyme-tPA chromogenic substrate, as described in Materials and Methods. 
The amount of cleaved substrate was determined by reading the sample absorbance at 
405 nm. The decreasing trend in A405 vs. the increasing PAI-1:tPA molar ratio indicates 
active PAI-1. Each data point represents the average of two samples (H-14-1B PAI-1) or 
a single sample (D-14-1B PAI-1). Lines are shown for clarity and do not represent fits to 









Figure 28: Dynamic light scattering characterization of PAI-1. 
To test for aggregated PAI-1, using conditions planned for PAI-1 preparation for SANS 
experiments, dynamic light scattering was performed with a Wyatt Technology 
instrument using a source wavelength of 690 nm.  PAI-1 was prepared in PBS, pH 7.4, 
0.15 M NaCl, and filtered through a 100-kDa filter. The single, large peak indicates a 
monodisperse sample, free from aggregation, while the position of the peak at 3 nm 
indicates a reasonable Rh for PAI-1, a 43-kDa protein. 
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The single peak centered at Rh 3 nm for a sample of PAI-1, indicates monodispersity and 
a reasonable size for PAI-1.  
 
Future Directions 
The successful expression and purification of active, deuterated PAI-1 is an exciting 
step toward experiments that can yield structural information regarding the enigmatic Vn-
PAI-1 complex. The methods developed for expression and purification of perdeuterated 
PAI-1 have already been used by others in our laboratory to prepare D-PAI-1 used in an 
initial set of SANS experiments, and can be used in other future work requiring 
deuterated PAI-1. Such future work is anticipated to include not only SANS but other 
experimental techniques as well. An example is NMR experimentation on the complex 









CHARACTERIZATION OF MONOCLONAL ANTIBODIES TO 





As discussed in Chapter 1, alternative means of gaining structural insight into 
vitronectin are needed. To that end, another aim involves an effort to crystallize 
vitronectin in complex with a monoclonal IgG antibody (mAb) or with the Fab fragment 
of a mAb. For this project, a panel of mAbs were screened for selection for use in 
crystallization trials, and an initial crystallization screen of Vn-mAb complex was set up. 
Crystallization of the complex was chosen because an antibody molecule may help a 
bound protein form a lattice. A separate set of screens is planned for the complex with the 
Fab fragment to take advantage of a different binding stoichiometry, with just one 
vitronectin binding to each Fab fragment rather than two, as in the case of the intact 
antibody. Three examples of the successful use of Fab fragments are the recent co-
crystallization of a complex of the SMB domain of vitronectin, uPA, and uPAR (with 
anti-uPAR Fab fragments) [70], and of two separate human immunodeficiency virus 
proteins [71-73].  
A monoclonal rather than a polyclonal antibody was used because all molecules of a 
monoclonal antibody are the same, binding to the same epitope, while polyclonal 
antibodies contain a mixture of molecules which bind to different epitopes. Because 
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crystallization of molecules requires homogeneity of sample, all antibodies must bind the 
antigen, vitronectin, the same way. 
The panel of mAbs screened offer the potential for many uses in our lab. The strategy 
for initial screening was interaction with both solid-phase (multimeric) and solution-
phase (monomeric, native) vitronectin, via enzyme-linked immunosorbent assay 
(ELISA). Based on results of these assays, three antibodies were selected for Vn-mAb 
complex characterization by size-exclusion HPLC. Others in our lab also have tested 
some of the mAbs for reactivity with vitronectin in immunoblots. 
 
Materials and Methods  
Materials 
Anti-vitronectin monoclonal antibodies were from either Molecular Innovations 
(1D1, 1E9, 2A10, 2C3, 4A1, 8H1), Green Mountain Antibodies, or Quidel. Peroxidase-
linked anti-mouse IgG from horse was from Vector Labs. Recombinant PAI-1 was from 
Molecular Innovations. Native vitronectin was isolated from human plasma, as described 
in Chapter 2 of this work. 
Non-competitive ELISA Titrations of Anti-vitronectin Monoclonal Antibodies 
Polystyrene 96-well plates (CoStar) were coated with vitronectin (0.5 µg/ml, 100 
µl/well) in 50 mM Na2CO3 buffer, pH 8.5, at room temperature for four hours or 
overnight. Plates were washed three times with TBS (20 mM Tris, 137 mM NaCl, 2.7 
mM KCl, pH 7.4) then blocked with 2% (w:v) BSA (Fraction V; Sigma) in TBS at room 
temperature for one hour. Plates were washed as before. An anti-vitronectin monoclonal 
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antibody, diluted 1:250 in 0.2% BSA in TBS, was serially diluted 1:4 from row to row, 
with a final volume of 80 µl/well. (For antibodies that were found to result in a weak 
signal after plate development, the assay was repeated using 1:1 serial dilutions. For 
antibodies that resulted in a saturated signal at the original dilutions, the assay was 
repeated using starting antibody dilutions of 1:1000 or 1:6250.) Plates were incubated at 
room temperature for one hour before being washed as before. One-hundred microliters 
of secondary antibody (peroxidase-linked anti-mouse IgG from horse), diluted 1:1000 in 
0.2% BSA in TBS, was added to each well and incubated at room temperature for one 
hour. Plates were washed as before, and then developed by addition of 100 µl developing 
solution [50 mM sodium citrate, pH5.5, 0.02% (w:v) ABTS, 0.05% (v:v) 30% H2O2] to 
each well. Absorbance at 405 nm was read on a Wallac Victor2 1420 label counter, at 
five-minute intervals, up to 30 minutes. 
Competitive ELISA Titrations of Anti-vitronectin Monoclonal Antibodies 
Polystyrene 96-well plates (CoStar) were coated with vitronectin and blocked as for 
the non-competitive ELISA described above. A control for no antigen and no antibody 
was set up in one row with addition of 100 µl 0.2% BSA (in TBS) only. A control for no 
antigen was set up by filling another row with 50 µl 0.2% BSA plus 50 µl monoclonal 
antibody at the appropriate dilution (1:250, 1:1000 or 1:6250). A serial dilution of 
competing antigen – Vn – was set up by filling the next row with 100 µl of a 20 µg/ml 
solution of vitronectin in TBS containing 0.2% BSA, and filling subsequent rows with 50 
µl 0.2% BSA in TBS. Fifty microliters from the antigen row was removed and serially 
diluted 1:1 in subsequent rows, with a final volume of 50 µl/well. Fifty microliters mAb 
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at the appropriate dilution was added to all rows containing vitronectin. Plates were 
incubated at room temperature for 1 hour, then washed three times as before. Addition of 
secondary antibody, development of plates, and absorbance reading were performed as 
described for the non-competitive assay above. 
Characterization of Vn-mAb Complexes by HPLC 
Size-exclusion HPLC, using a Phenomenex Biosep SEC-S3000 column (300 x 7.8 
mm; MW range 5-700 kDa), attached to a Hewlett-Packard 1100 series HPLC system, 
was utilized to observe complex formation of vitronectin with monoclonal antibodies or 
with Fab. Absorbance was detected in the instrument flow cell at 280 and 220 nm. The 
column was equilibrated with PBS, pH 7.4; flow rate was 0.5 ml/min. Vitronectin and 
mAb were mixed in molar ratios of 0.5:1, 1:1, 2:1, 2.5:1, 3:1 or 4:1; incubated at room 
temperature for 1 min; and 15 - 50 µl injected into the 50-µl loop. Fractions (0.5 ml or 
0.25 ml) were analyzed by SDS-PAGE to confirm components of peaks.  
Crystallization Screen of Vn-1E9 Complex 
Both vitronectin and monoclonal antibody 1E9 were dialyzed into crystallization 
buffer (50 mM HEPES, pH 7.0, 0.15 M NaCl). Vitronectin at 3.6 mg/ml (58 µM) was 
mixed with 1E9 at 3.3 mg/ml (22 µM), giving a molar ratio of 2.6:1, Vn:1E9. One 
milliliter of the mixture (3.45 mg total protein) was loaded on an FPLC Superdex 200 
column to isolate the complex by size exclusion; flow rate was 0.5 ml/min. Protein-rich 
fractions were identified by absorbance at 280 nm, and protein content of these fractions 
was analyzed by SDS-PAGE.  Eight 1-ml fractions were pooled from the center of the 
elution peak shown to include both proteins. Containing a total of approximately 2 mg of 
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protein, the pool was concentrated to a final volume of 200 µl, for a concentration of 10 
mg/ml. This sample and the screening components were equilibrated to room temperature 
to match the crystallization conditions, and crystallization screens were set up 
immediately. 
The hanging drop vapor diffusion method was used to screen 120 different conditions 
in 24-well trays. For initial evaluation of protein solubility, the Classics Suite from 
Nextal Biotechnologies was used for 96 conditions. For another 24 conditions, to screen 
for preliminary crystallization conditions for intact antibodies, the Low Ionic Strength 
Screen from Hampton Research was used. The remaining 84 conditions included in the 
Hampton screen were postponed due to a lack of protein. Samples were monitored by 
light microscopy at set-up, and every few days for two weeks, then weekly for four 
weeks, then every few weeks, up to 10 months after setting up the screens.  
SDS-PAGE 
Proteins were electrophoresed on a 10% polyacrylamide SDS gel. Protein bands were 
visualized either by staining with Coomassie blue followed by destaining with glacial 
acetic acid and methanol, or by staining with GelCode Blue Stain Reagent (Pierce) 
followed by destaining with water. 
 
Results and Discussion 
Characterization of Antibodies by ELISA 
Eight monoclonal antibodies specific for vitronectin were characterized with regard to 
their interaction with monomeric (native) and multimeric vitronectin, and the vitronectin-
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PAI-1 complex. Non-competitive ELISA was used first to determine the working 
concentration of each antibody, i.e., the concentration resulting in adequately strong 
binding to solid-phase vitronectin on the plate. These concentrations were used in 
competitive ELISAs to determine which antibodies bound well to native vitronectin in 
solution. Those that bound well showed a concentration-dependent decrease in binding to 
the solid-phase vitronectin, as the solution-phase vitronectin competed for mAb binding. 
Figures 29 and 30 show the ELISA results. Three mAbs – 1D1, 1E9, and a commercial 
antibody obtained from Green Mountain (GM) – clearly interact more strongly with both 
native and solid-phase vitronectin than do the others. This is reflected in the higher 
absorbance observed in the non-competitive ELISA, along with the decreasing 
absorbance seen as the native vitronectin concentration increases in the competitive 
ELISA. 
Because of their superior interaction with vitronectin, antibodies 1D1, 1E9, and GM 
were selected for further evaluation of their suitability for co-crystallization screens. Four 
additional mAbs were selected for further assessment of their potential for other uses in 
our laboratory. These four mAbs were 2A10, 2C3, 8H1, and a commercial antibody 
obtained from Quidel (Q). Due to poor performance in both non-competitive and 
competitive ELISAs, mAb 4A1 was not tested further. 
Characterization of Vn-mAb Complexes by HPLC 
Size-exclusion HPLC was used for further analysis of Vn-mAb complex formation. 
Surprisingly, only one of the three candidates for co-crystallization screens formed 
complexes with vitronectin detectable by HPLC: 1E9. Samples of 1D1 or GM mAb 

















Figure 29: Anti-Vn mAb titrations by ELISA. 
Monoclonal antibodies specific for Vn were tested for interaction with multimeric Vn 
(5 µg/ml) coated on ELISA plates. Each mAb was serially diluted and allowed to interact 
with Vn for 1 h; bound mAb was incubated with peroxidase-linked anti-mouse IgG for 
1 h. Plates were developed with a solution containing ABTS and H2O2. Absorbance was 
read at 405 nm. MAbs tested include Q, open circles; GM, open squares; 1D1, open 
diamonds; 1E9, open right triangles; 2A10, closed inverted triangles; 4A1, open 
triangles; 8H1, closed circles; 2C3, closed squares. Lines are shown for clarity and do 
not represent fits to the data. For a given mAb concentration, a higher A405 indicates a 
















Figure 30: Anti-Vn mAb competitive ELISA. 
Monoclonal antibodies specific for Vn were tested for interaction with native Vn. Each 
mAb was allowed to interact with serially diluted, native Vn (in solution) for 1 h in 
ELISA plates coated with multimeric Vn (5 µg/ml); mAb not captured by native Vn had 
the potential to bind to the Vn-coated plate. After the incubation with native Vn, bound 
mAb was incubated with peroxidase-linked anti-mouse IgG for 1 h. Plates were 
developed with a solution containing ABTS and H2O2. Absorbance was read at 405 nm. 
MAbs tested include Q, open circles; GM, open squares; 1D1, open diamonds; 1E9, 
open right triangles; 2A10, closed inverted triangles; 4A1, open triangles; 8H1, closed 
circles; 2C3, closed squares. Lines are shown for clarity and do not represent fits to the 
data. Decreasing A405 in response to increasing Vn in solution indicates interaction of 
mAb with native Vn. MAb concentrations used for competitive ELISAs, determined by 
titrations as described in the legend to Figure 28, were Q, 0.6 µg/ml; GM, 0.052 µg/ml; 
1D1, 0.3 µg/ml; 1E9, 0.32 µg/ml; 2A10, 20 µg/ml; 4A1, 40 µg/ml; 8H1, 1.0 µg/ml; 2C3, 
0.86 µg/ml. 
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vitronectin. In contrast, Vn-1E9 samples eluted as either two or three peaks, depending 
on  the ratio of  Vn:mAb;  importantly,  one  peak  always  present  corresponded  to  the 
complex. The chromatograms for the various Vn:mAb ratios tested, as well as for Vn and 
1E9 alone, are shown in Figure 31. 
The ratio of Vn:1E9 that produced the most complex and the least unbound proteins 
was 2:1. This was judged by a comparison of the peak heights relative to each other for 
each sample. The 2:1 sample had the highest peak corresponding to complex relative to 
the peaks corresponding to free proteins. Any increase in Vn greater than 2:1 resulted in 
an increase in only the peak from free Vn. For co-crystallization screens, all unbound 
protein must be removed to produce a homogeneous sample. This separation is most 
easily accomplished for samples containing minimal free protein. Therefore, 1E9 in a 
ratio of 2:1 Vn:mAb was selected for crystallization screens. 
Besides 1E9, only 2C3 formed a complex with vitronectin that was detectable by 
HPLC analysis.  However, the 2C3-Vn complex was present in only a small amount. 
Results of the characterization of the eight anti-vitronectin mAbs are summarized in 
Table 2. 
Crystallization Screen of Vn-1E9 Complex 
Purified Vn-1E9 complex was obtained by chromatographing a mixture of Vn and 
1E9 on an FPLC Superdex 200 column. A successful peak separation can be seen on the 
chromatogram shown in Figure 32. The pool from the complex peak was concentrated to 
10 mg/ml for the crystallization screen. The hanging drop vapor diffusion method was 
used to screen 120 different crystallization conditions for the purified complex of Vn-E9. 






















































































Figure 31: Size-exclusion HPLC analysis of Vn-1E9 complex formation. 
Proteins were mixed in the molar ratios indicated (Vn:1E9) and incubated for one min 
before loading column (Phenomenex Biosep SEC-S3000 column, 300 x 7.8 mm) with 15 
- 50 µl sample via a 50-µl loop. Column was equilibrated in PBS, pH 7.4; flow rate was 
0.5 ml/min. Retention times, in min: Vn, 20.9; 1E9, 19.8; complex, 16.8-17.3. The 2:1 
Vn:1E9 sample produced the most complex with the least unbound protein. 
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Table 2: Summary of anti-vitronectin mAb characterization 








Good Binding Competition No Complex 
1E9 
 
Good Binding Competition Complex 
2A10 
 














Weak Binding No Competition No Complex 
Green Mtn 
 
Good Binding Competition No Complex 
Quidel 
 
Moderate Binding Competition Inconclusive 
























Figure 32: Size-exclusion FPLC isolation of Vn-1E9 complex for crystallization 
screen. 
Vitronectin (58 µM) and mAb 1E9 (22 µM), both prepared in 50 mM HEPES, pH 7.0, 
0.15 M NaCl, were mixed in a molar ratio of 2.6:1. The complex was isolated by size-
exclusion chromatography of the mixture on an FPLC Superdex 200 column with a flow 
rate of 0.5 ml/min. Protein-rich fractions were identified by absorbance at 280 nm. 
Protein content of each chromatogram peak, confirmed by SDS-PAGE, is indicated. 
Fractions from the Vn-1E9 peak (indicated by the bar) were pooled, concentrated, and 
used to set up a crystallization screen, as described in Materials and Methods. 
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However,  no  conditions  produced  formations  promising enough  to warrant condition 
optimization. This is not surprising, given that intact IgGs have a hinge region that makes 
the molecule flexible. Complex formation with IgG fragments, such as Fab or Fv, which 
do not have the hinge region, is more commonly used for attempted crystallizations [71]. 
 
Concluding Remarks and Future Directions 
The characterization of a panel of eight monoclonal antibodies to vitronectin resulted 
in selection of mAb 1E9 for co-crystallization screens with vitronectin. Although the 
initial screens did not produce crystals, the same antibody can be used to provide Fab  
fragments for a future co-crystallization screen with vitronectin. This option is promising 
because the Fab  fragment does not have the flexible hinge region of the intact antibody, 
and it offers a different stoichiometry due to its single binding site. 
The information gained from the characterization of these antibodies will be valuable 
to our laboratory in the future. For example, strategic choices can be made about their use 
in immunoblotting, plate assays, and surface plasmon resonance binding experiments. 
Additional characterization of these antibodies that would be useful is epitope mapping of 
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